QuickLinks
-- Click here to rapidly navigate through this document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy
Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
|
|
|
Filed by the Registrant
ý
|
Filed by a Party other than the Registrant
o
|
Check the appropriate box:
|
o
|
|
Preliminary Proxy Statement
|
o
|
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
ý
|
|
Definitive Proxy Statement
|
o
|
|
Definitive Additional Materials
|
o
|
|
Soliciting Material under §240.14a-12
|
|
|
|
|
|
Acceleron Pharma Inc.
|
(Name of Registrant as Specified In Its Charter)
|
|
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
|
Payment of Filing Fee (Check the appropriate box):
|
ý
|
|
No fee required.
|
o
|
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
|
(1)
|
|
Title of each class of securities to which transaction applies:
|
|
|
(2)
|
|
Aggregate number of securities to which transaction applies:
|
|
|
(3)
|
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
|
(4)
|
|
Proposed maximum aggregate value of transaction:
|
|
|
(5)
|
|
Total fee paid:
|
o
|
|
Fee paid previously with preliminary materials.
|
o
|
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.
|
|
|
(1)
|
|
Amount Previously Paid:
|
|
|
(2)
|
|
Form, Schedule or Registration Statement No.:
|
|
|
(3)
|
|
Filing Party:
|
|
|
(4)
|
|
Date Filed:
|
Acceleron Pharma Inc.
128 Sidney Street
Cambridge, MA 02139
NOTICE OF 2014 ANNUAL MEETING OF STOCKHOLDERS
The 2014 Annual Meeting of Stockholders of Acceleron Pharma Inc. (the "Company" or "Acceleron") will be held on June 20, 2014, at 11:00 a.m.
local time, at Ropes & Gray LLP, Prudential Tower, 800 Boylston Street, Boston, MA 02199 for the following purpose of considering two company-sponsored proposals:
1. To
elect Jean M. George, Edwin M. Kania and George Golumbeski, Ph.D. as Class I directors, each for a three-year term;
2. To
ratify the appointment of Ernst & Young, LLP as the independent registered public accounting firm for the Company for the fiscal year ending
December 31, 2014.
We
will also consider and act upon any other matters that properly come before the Annual Meeting or any adjournment or postponement thereof.
Our
board of directors recommends that you vote "for" each of the nominees for Class I director (proposal no. 1) and "for" ratification of the proposed independent
accounting firm (proposal no. 2).
Each
outstanding share of the Company's common stock (NASDAQ: XLRN) entitles the holder of record at the close of business on April 21, 2014, to receive notice of and to vote at
the Annual Meeting or any adjournment or postponement of the Annual Meeting.
Whether
or not you expect to attend the meeting, we urge you to vote your shares by internet, telephone, or by signing, dating and returning the proxy card included in these materials.
If you choose to attend the annual meeting, you may still vote your shares in person, even if you have previously voted or returned your proxy by any of the methods described in our proxy statement.
If your shares are held in a bank or brokerage account, please refer to the materials provided by your bank or broker for voting instructions.
All
stockholders are extended a cordial invitation to attend the meeting.
|
|
|
|
|
By Order of the Board of Directors
|
|
|
|
|
|
John L. Knopf, Ph.D.
Chief Executive Officer, President and Director
May 9, 2014
|
Acceleron Pharma Inc.
128 Sidney Street
Cambridge, MA 02139
PROXY STATEMENT FOR 2014 ANNUAL MEETING OF STOCKHOLDERS
To Be Held On Friday, June 20, 2014 at 11:00 am EDT
GENERAL INFORMATION
When are this proxy statement and the accompanying material scheduled to be sent to stockholders?
This proxy statement and accompanying proxy card or, for shares held in street name (held for your account by a broker or other
nominee), voting instruction form, are scheduled to be sent to stockholders beginning on May 9, 2014.
Who is soliciting my vote?
The Board of Directors of the Company is soliciting your vote for the 2014 Annual Meeting of Stockholders.
When is the record date for the Annual Meeting?
The Company's Board of Directors has fixed the record date for the Annual Meeting as of the close of business on April 21, 2014.
How many votes can be cast by all stockholders?
A total of 31,450,419 shares of common stock of the Company were outstanding on April 21, 2014 and are entitled to be voted at
the meeting. Each share of common stock is entitled to one vote on each matter.
How do I vote?
If you are a stockholder of record and your shares are registered directly in your name, you may vote:
-
-
By
Internet.
You may vote by proxy via the internet at www.proxyvote.com by following the instructions provided on the notice of internet
availability of proxy materials or the proxy card.
-
-
By
Telephone.
If you live in the United States or Canada, you may vote by proxy by calling toll-free 1-800-690-6903 and by following the
instructions provided on the proxy card. You must have the control number that is on either the notice or the proxy card when voting.
-
-
By
Mail.
Complete and mail your proxy card in the postage prepaid envelope you receive, and return the proxy card to Vote Processing, c/o
Broadridge, 51 Mercedes Way, Edgewood, NY 11717. Your proxy will be voted in accordance with your instructions. If you sign and return the enclosed proxy but do not specify how you want
your shares voted, they will be voted
FOR
the election of the director nominees named herein to the Company's Board of Directors, and
FOR
the ratification
of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending
December 31, 2014 and will be voted according to the discretion of the proxy holder named in the proxy card upon any other business that may properly be brought before the meeting and at all
adjournments and postponements thereof.
-
-
In Person at the
Meeting.
If you attend the meeting, be sure to bring a form of personal picture identification with you, and you may deliver your
completed proxy card in person, or you may vote by completing a ballot, which will be available at the meeting.
If
your shares of common stock are held in street name (held for your account by a broker or other nominee):
-
-
By Internet or By
Telephone.
You will receive instructions from your broker or other nominee if you are permitted to vote by internet or telephone.
-
-
By
Mail.
You will receive instructions from your broker or other nominee explaining how to vote your shares.
-
-
In Person at the
Meeting.
If you attend the meeting, in addition to picture identification, you should both bring an account statement or a letter from
the record holder indicating that you owned the shares as of the record date,
and
contact the broker or other nominee who holds your shares to obtain a
broker's proxy card and bring it with you to the meeting.
What are the Board's recommendations on how to vote my shares?
The Board of Directors recommends a vote:
Proposal
1: FOR election of Jean M. George, Edwin M. Kania and George Golumbeski, Ph.D. as Class I directors.
Proposal
2: FOR ratification of selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31,
2014.
Who pays the cost for soliciting proxies?
Acceleron will bear the cost of solicitation of proxies. This includes the charges and expenses of brokerage firms and others for
forwarding solicitation material to beneficial owners of our outstanding common stock. Acceleron may solicit proxies by mail, personal interview, telephone or via the internet through its officers,
directors and other management employees, who will receive no additional compensation for their services.
Can I change my vote?
You may revoke your proxy at any time before it is voted by notifying the Secretary in writing, by returning a signed proxy with a
later date, by transmitting a subsequent vote over the internet or by telephone prior to the close of the internet voting facility or the telephone voting facility, or by attending the meeting and
voting in person. If your stock is held in street name, you must contact your broker or nominee for instructions as to how to change your vote.
How is a quorum reached?
The presence, in person or by proxy, of holders of at least a majority of the total number of outstanding shares entitled to vote is
necessary to constitute a quorum for the transaction of business at the Annual Meeting. Abstentions and "broker non-votes" (i.e., shares represented at the meeting held by brokers, bankers or
other nominees as to which instructions have not been received from the beneficial owners or persons entitled to vote such shares and, with respect to one or more but not all issues, such brokers or
nominees do not have discretionary voting power to vote such shares), if any, will be counted for purposes of determining whether a quorum is present for the transaction of business at the meeting.
What vote is required to approve each item?
Directors are elected by a plurality of votes cast. A vote to abstain or a broker non-vote will have no direct effect on the outcome. A
majority of votes cast is necessary for ratification of the selection of
2
Ernst &
Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2014 (Proposal 2). A vote to abstain will have no direct
effect on the outcome.
If
there are insufficient votes to approve these proposals, your proxy may be voted by the persons named in the proxy card to adjourn the Annual Meeting in order to solicit additional
proxies in favor of the approval of such proposal(s). If the Annual Meeting is adjourned or postponed for any purpose, at any subsequent reconvening of the meeting, your proxy will be voted in the
same manner as it would have been voted at the original convening of the Annual Meeting unless you withdraw or revoke your proxy.
Could other matters be decided at the Annual Meeting?
Acceleron does not know of any other matters that may be presented for action at the Annual Meeting. Should any other business come
before the meeting, the persons named on the enclosed proxy will have discretionary authority to vote the shares represented by such proxies in accordance with their best judgment. If you hold shares
through a broker, bank or other nominee as described above, they will not be able to vote your shares on any other business that comes before the Annual Meeting unless they receive instructions from
you with respect to such matter.
What happens if the meeting is postponed or adjourned?
Your proxy may be voted at the postponed or adjourned meeting. You will still be able to change your proxy until it is voted.
What does it mean if I receive more than one proxy card or voting instruction form?
It means that you have multiple accounts at the transfer agent or with brokers. Please complete and return all proxy cards or voting
instruction forms to ensure that all of your shares are voted.
Who should I call if I have any additional questions?
If you hold your shares directly, please call John Quisel, Secretary of the Company, at (617) 649-9200. If your shares are held
in street name, please contact the telephone number provided on your voting instruction form or contact your broker or nominee holder directly.
3
PROPOSAL NO. 1ELECTION OF DIRECTORS
In accordance with the Company's certificate of incorporation and bylaws, the Board of Directors is divided into three classes of
approximately equal size. The members of each class are elected to serve a three-year term with the term of office of each class ending in successive years. Jean M. George, Edwin M. Kania Jr. and
George Golumbeski, Ph.D. are the Class I directors whose terms expire at the Company's 2014 Annual Meeting of stockholders and each of Ms. George, Mr. Kania and
Dr. Golumbeski has been nominated for and has agreed to stand for re-election to the Board of Directors to serve as a Class I director of the Company for three years and until their
successors are duly elected and qualified or until their earlier death, resignation or removal.
The
three nominees for director with the highest number of affirmative votes will be elected as directors. It is intended that, unless you give contrary instructions, shares represented
by proxies will be voted for the election of the three nominees listed above as director nominees. Acceleron has no reason to believe that any nominee will be unable to serve. In the event that one or
more nominees is unexpectedly not available to serve, proxies may be voted for another person nominated as a substitute by the Board of Directors, or the Board of Directors may reduce the number of
directors to be elected at the Annual Meeting. Information relating to each nominee for election as director and for each continuing director, including his or her period of service as a director of
Acceleron, principal occupation and other biographical material is shown below.
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE FOR EACH OF
THESE NOMINEES FOR CLASS I DIRECTOR
(PROPOSAL 1 ON YOUR PROXY CARD)
4
DIRECTORS AND CORPORATE GOVERNANCE
BOARD COMPOSITION AND STRUCTURE
Our certificate of incorporation states that our board shall consist of not fewer than three and not more than fifteen members, and the
precise number of directors shall be fixed by a resolution of our board. Each director holds office until his or her successor is duly elected and qualified or until his or her death, resignation or
removal. Our certificate of incorporation provides that our directors may be removed only for cause by the affirmative vote of the holders of at least seventy-five percent (75%) of the voting power of
the outstanding shares of capital stock of the Company entitled to vote generally in the election of directors, voting together as a single class, at a meeting of the stockholders called for that
purpose. Any vacancy in the board, including a vacancy that results from an increase in the number of directors, may be filled by a vote of the majority of the directors then in office.
Our
certificate of incorporation provides that our board of directors is divided into three classes of directors, with the classes as nearly equal in number as possible. Each of our
directors identified below serves in the class indicated. Subject to any earlier resignation or removal in accordance with the terms of our restated certificate of incorporation and bylaws, our
Class I directors will serve until the 2014 annual meeting of stockholders; our Class II directors will serve until the 2015 annual meeting of stockholders; and our Class III
directors will serve until the 2016 annual meeting of stockholders. Any
additional directorships resulting from an increase in the number of directors will be apportioned by our board among the three classes.
Our
board of directors is currently comprised of 8 members, with one vacancy in class II resulting from the resignation of Anthony B. Evnin, Ph.D. on February 27, 2014.
Below is a list of the names, ages as of March 31, 2014 and classification of the individuals who currently serve as our directors.
|
|
|
|
|
|
Name
|
|
Age
|
|
Position
|
Jean M. George
|
|
|
56
|
|
Director (Class I)
|
George Golumbeski, Ph.D.
|
|
|
56
|
|
Director (Class I)
|
Edwin M. Kania, Jr.
|
|
|
56
|
|
Director (Class I)
|
John L. Knopf, Ph.D.
|
|
|
61
|
|
Director (Class II); Chief Executive Officer and President
|
Terrance G. McGuire
|
|
|
58
|
|
Director (Class II)
|
Tom Maniatis, Ph.D.
|
|
|
70
|
|
Director (Class III)
|
Richard F. Pops
|
|
|
52
|
|
Director (Class III)
|
Joseph S. Zakrzewski
|
|
|
51
|
|
Director (Class III)
|
DIRECTOR BIOGRAPHIES
Information concerning our directors is set forth below. The biographical description of each director includes the specific
experience, qualifications, attributes and skills that the Board of Directors would expect to consider if it were making a conclusion currently as to whether such person should serve as a director.
CLASS I DIRECTOR NOMINEES
Jean M. George
has served as a member of our board of directors since 2005. Since 2002,
Ms. George has been a Managing Director at Advanced Technology Ventures (ATV), and, concurrently since April 2013, Ms. George has been a Managing Director at LSV Capital Management. She
joined ATV in 2002 and serves as the firm's East Coast lead partner for healthcare investments. Prior to joining ATV, Ms. George was a Director at BancBoston Ventures, where she led the health
care team's investment activity in NuGenesis Technologies Corp., Microbia, Inc., Syntonix Pharmaceuticals, Inc. and Neurometrix, Inc. Before BancBoston Ventures, she worked at
Genzyme Corporation from 1988 to 1998, where she held a variety of operational roles in marketing, product development, and business
5
development,
including Vice President of Global Sales and Marketing. She also worked as a Vice President and Founder of Genzyme's Tissue Repair Division. She is currently a Director of one other
public company, Zeltiq Aesthetics, Inc., and several private companies, including Calithera Biosciences, Hydra Biosciences, Inc., Thrasos Therapeutics and Catabasis
Pharmaceuticals, Inc. Ms. George was a Director of Hypnion, Inc., Critical Therapeutics, Inc., Portola Pharmaceuticals, Inc. and Proteolix, Inc. She was named
a member of the Scientific Advisory Board for the Massachusetts Life Sciences Center. Ms. George received a BS in biology from the University of Maine and an MBA from Simmons College Graduate
School of Management. We believe that Ms. George's executive experience in the life sciences and therapeutic device industries qualifies her to serve as a member of our board of directors.
Edwin M. Kania, Jr.
has served as a member of our board of directors since 2004. Since 2000, Mr. Kania has been a Managing Partner
and the Chairman of Flagship Ventures, a Boston-based venture capital firm that he co-founded and that also manages the Applied Genomic Technology Capital Fund, L.P. (AGTC Fund) as well as
funds raised by OneLiberty Ventures. Prior to co-founding Flagship Ventures, Mr. Kania was a Managing Partner at OneLiberty Ventures and its predecessor firm,
Morgan Holland Ventures which he joined in 1985. Mr. Kania currently serves on the boards of several private companies. Mr. Kania has also served on the boards of Aspect Medical, EXACT
Sciences and other public and private companies. Mr. Kania's direct investment experience covers over 100 companies, and he has been intimately involved in the launch and development of more
than a dozen companies as the founding, lead or co-lead investor, and has on occasion assumed operating roles in support of management. Mr. Kania received a BS in physics from Dartmouth College
and an MBA from Harvard Business School. We believe that Mr. Kania's extensive experience investing in, guiding and leading start-up and early phase companies qualifies him to serve as a member
of our board of directors.
George Golumbeski, Ph.D.
has served as a member of our board of directors since 2011. Since 2009, Dr. Golumbeski has been a Senior
Vice President of Business Development for Celgene Corporation, where he is responsible for the full array of business development activities, including identification and evaluation of opportunities,
structuring and negotiating transactions, in-licensing, M&A, out-licensing, and alliance management. At Celgene, these activities are focused primarily within the therapeutic areas of oncology and
inflammation. From 2008 to 2009, Dr. Golumbeski served as the CEO of Nabriva Therapeutics AG. Prior to Nabriva, Dr. Golumbeski served as Vice President of Business Development, Licensing
and Strategy for Novartis-Oncology. During his tenure at Novartis, Dr. Golumbeski's group closed a significant number of collaboration agreements which bolstered the development pipeline.
Earlier in his career, Dr. Golumbeski held senior positions at Elan Pharmaceuticals and at Schwarz Pharma, where he led the effort to in-license rotigotine and lacosamide (now both approved
agents). He currently serves on the board of directors of one other public company, Enanta Pharmaceuticals, Inc. Dr. Golumbeski received a BA in biology from the University of Virginia
and a Ph.D. in genetics from the University of Wisconsin-Madison. We believe that Dr. Golumbeski's experience as an officer of other pharmaceutical companies, as well as Dr. Golumbeski's
extensive experience in research and development and corporate leadership positions, qualify him to serve as a member of our board of directors.
CURRENT DIRECTORS NOT STANDING FOR ELECTION AT THE ANNUAL MEETING
John L. Knopf, Ph.D.
co-founded Acceleron in 2003 and is our Chief Executive Officer
and President. Dr. Knopf served on our board of directors from 2003 to 2004, and has served from 2007 to the present. Prior to founding Acceleron, Dr. Knopf served as Site Head of the
Wyeth Research facilities in Cambridge, MA and Vice President of Metabolic and Respiratory Disease. Dr. Knopf was an early key scientist at Genetics Institute (GI) from 1982 to 1998, where he
participated in the development of pioneering biopharmaceutical products including the first treatment for hemophilia, recombinant factor VIII
Recombinate
® and helped establish GI as a premier
biopharmaceutical
6
company.
While at GI, he established a structure-based small molecule discovery group. Dr. Knopf is the author of several key scientific manuscripts in the area of signal transduction, and is
named as an inventor of several patents. Dr. Knopf received a BS in biology from SUNY Stonybrook and his Ph.D. in biology at SUNY Buffalo. We believe Dr. Knopf's extensive experience and
knowledge of biopharmaceuticals and our company qualifies him to serve as a member of our board of directors.
Tom Maniatis, Ph.D.
co-founded Acceleron in 2003 and has served as a member of our board of directors and chair of our Scientific Advisory
Board since 2003. Since 2010 he has been a Professor and Chair of the Department of Biochemistry & Molecular Biophysics at the Columbia University College of Physicians and Surgeons. Prior to
working at Columbia, Dr. Maniatis was a professor at Harvard University where he studied the mechanisms of transcription and RNA splicing in eukaryotes. Dr. Maniatis currently serves on
the board of one private company, Constellation Pharmaceuticals, Inc. Dr. Maniatis is also a co-founder of Genetics Institute and ProScript Inc., where he served on the board of
directors. Dr. Maniatis is a member of the U.S. National Academy of Sciences, and has received numerous awards for his research contributions, including the Eli Lilly Research Award in
Microbiology and Immunology, the Richard Lounsbery Award for Biology and Medicine from the U.S. and French National Academies of Science, and the 2012 Lasker-Koshland Special Achievement Award in
Medical Science. Dr. Maniatis received a BA in biology, an MS in chemistry from the University of Colorado at Boulder, and a Ph.D. in molecular biology from Vanderbilt University. We believe
Dr. Maniatis's extensive experience and knowledge of biopharmaceuticals and the biopharmaceutical industry qualify him to serve as a member of our board of directors.
Terrance G. McGuire
has served as a member of our board of directors since 2005. Mr. McGuire co-founded Polaris Partners in 1996
and is currently one of their general partners. Prior to starting Polaris Partners, Mr. McGuire spent seven years at Burr, Egan, Deleage & Co., investing in early stage medical
and information technology companies. He currently serves on the board of directors of two other public companies, Ironwood Pharmaceuticals and Trevena. He also serves on the boards of several private
companies, including Adimab/Arsanis, Alector, Quantum Designs, Arsenal Medical/480 Biomedical, Editas, Iora Health, Life Line Screening, MicroCHIPS, NextCode, Pulmatrix, and SustainX. He has
formerly served on the board of directors of Remon Medical Technologies, GlycoFi, Akamai Technologies, Aspect Medical Systems, Cubist Pharmaceuticals, Transform Pharma, and deCODE genetics, among
others. Mr. McGuire is the former chairman of the National Venture Capital Association, chairman of the board of the Thayer School of Engineering at Dartmouth College, and a member of the
boards of The David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology and The Arthur Rock Center for Entrepreneurship at Harvard Business School.
Mr. McGuire earned a BS in physics and economics from Hobart College, an MS in engineering from The Thayer School at Dartmouth College, and an MBA from Harvard Business School. We believe that
Mr. McGuire's extensive experience as a venture capitalist focused on the biotechnology industry, as well as Mr. McGuire's many years of experience helping companies evolve from the
start-up phase to successful public companies qualify him to serve as a member of our board of directors.
Richard F. Pops
has served as a member of our board of directors since 2004. Since 2011, Mr. Pops has served as Chief Executive
Officer and Chairman of the board of Alkermes plc, the parent company of
Alkermes. From 2009 to 2011, Mr. Pops served as Chief Executive Officer and Chairman of the Board of Alkermes, from 2007 to 2009 he served as the Chairman of the board of Alkermes, and from
1991 through 2007 he served as the Chief Executive Officer of Alkermes. Mr. Pops also serves on the board of directors of two other public companies, Neurocrine Biosciences, Inc. and
Epizyme Inc., and on the board of directors for the Biotechnology Industry Organization (BIO) and Pharmaceutical Researcher and Manufacturers of America (PhRMA). He has previously served on the
board of directors of Sirtris Pharmaceuticals from 2004 to 2008, and CombinatoRx, Inc. from 2001 to 2009. Mr. Pops also served on the board of directors of Reliant Pharmaceuticals, a
privately held pharmaceutical company purchased by GlaxoSmithKline in 2007, and on the advisory board of Polaris
7
Venture
Partners. He was a member of the Harvard Medical School Board of Fellows from 2002 through June 2012. Mr. Pops received a BA in economics from Stanford University. We believe that
Mr. Pops leadership experience and industry knowledge qualify him to serve as a member of our board of directors.
Joseph S. Zakrzewski
has served as a member of our board of directors since 2011. Since 2010 and through 2013, Mr. Zakrzewski had
been Chairman and Chief Executive Officer of Amarin Corporation. From 2007 to 2010, Mr. Zakrzewski served as President and Chief Executive Officer of Xcellerex. From 2005 to 2007,
Mr. Zakrzewski served as the Chief Operating Officer of Reliant Pharmaceuticals, overseeing the launch of Omacor®, a drug to treat elevated triglyceride levels. From 1988 to 2004,
Mr. Zakrzewski served in a variety of positions at Eli Lilly and Company including as Vice President, Corporate Business Development from 2003 through 2004. In addition, Mr. Zakrzewski
served as a Venture Partner with OrbiMed in 2010 and 2011. Mr. Zakrzewski also currently serves on the board of directors of two other public companies, Amarin and Insulet Corporation, and has
also served on the board of directors of Xcellerex, Azelon/Zelos Therapeutics and Promedior. Mr. Zakrzewski received a BS in Chemical Engineering and an MS in Biochemical Engineering from
Drexel University as well as an MBA in Finance from Indiana University. We believe that Mr. Zakrzewski's substantial experience as an executive officer of other pharmaceutical companies, as
well as Mr. Zakrzewski's service on boards of directors of other pharmaceutical companies qualify him to serve as a member of our board of directors.
Director Independence
Under NASDAQ Rule 5605, a majority of a listed company's board of directors must be comprised of independent directors. In
addition, NASDAQ rules require that, subject to specified exceptions, each member of a listed company's audit committee and compensation committee be independent and satisfy additional independence
criteria set forth in Rule 10A-3 and 10C-1, respectively, under the Securities Exchange Act of 1934, or the Exchange Act. Under NASDAQ
Rule 5605(a)(2), a director will only qualify as an "independent director" if, in the opinion of that company's board of directors, that person does not have a relationship that would interfere
with the exercise of independent judgment in carrying out the responsibilities of a director.
Based
upon information requested from and provided by each director concerning their background, employment and affiliations, including family relationships, our board of directors has
determined that each of Ms. George and Messrs. Golumbeski, Kania, Maniatis, McGuire, Pops and Zakrzewski, representing seven of our eight directors, is "independent" as that term is
defined under NASDAQ Rule 5605(a)(2). Our board of directors also determined that each of the current members of our audit committee and our compensation committee satisfies the independence
standards for such committee established by Rule 10A-3 and 10C-1 under the Exchange Act, the SEC rules and the NASDAQ rules, as applicable. In making such determination, our board of directors
considered the relationships that each such non-employee director has with our Company and all other facts and circumstances deemed relevant in determining their independence.
The
members of our board of directors were elected in compliance with the provisions of a voting agreement among us and our major stockholders. The voting agreement terminated upon the
closing of our initial public offering on September 24, 2013, and at present we do not have any contractual obligations regarding the election of our directors. See "Certain Relationships and
Related Party Transactions". There are no family relationships among any of our directors or executive officers.
Board Meetings and Attendance
The Board of Directors held five meetings during the year ended December 31, 2013. Each of the directors attended at least
seventy-five percent (75%) of the meetings of the Board of Directors and
8
the
committees of the Board of Directors on which he or she served during the year ended December 31, 2013 (in each case, which were held during the period for which he or she was a director
and/or a member of the applicable committee).
The
non-management directors met in executive session during each of four regularly scheduled Board of Directors meetings during the year ended December 31, 2013.
Board of Directors Leadership Structure
We have not designated a chair or a lead director for our Board of Directors meetings. The independent members of the Board of
Directors have periodically reviewed the Board's leadership structure and have determined that Acceleron and our stockholders are well served with this structure.
The Board of Directors' Role in Risk Oversight
The Board of Directors plays an important role in risk oversight at Acceleron through direct decision-making authority with respect to
significant matters, as well as through the oversight of management by the Board of Directors and its committees. In particular, the Board of Directors administers its risk oversight function through
(1) the review and discussion of regular periodic reports by the Board of Directors and its committees on topics relating to the risks that Acceleron faces, (2) the required approval by
the Board of Directors (or a committee of the Board of Directors) of significant transactions and other decisions, (3) the direct oversight of specific areas of Acceleron's business by the
Audit, Compensation and Nominating and Corporate Governance Committees, and (4) regular periodic reports from the auditors and other outside consultants regarding various areas of potential
risk, including, among others, those relating to our internal control over financial reporting. The Board of Directors also relies on management to bring significant matters impacting Acceleron to the
attention of the Board of Directors.
Pursuant
to the Audit Committee's charter, the Audit Committee is responsible for reviewing and discussing with management and Acceleron's independent registered public accounting firm,
Acceleron's system of internal control, its critical accounting practices, and policies relating to risk assessment and management. As part of this process, the Audit Committee discusses Acceleron's
major financial risk exposures and steps that management has taken to monitor and control such exposure. In addition the Audit Committee has established procedures for the receipt, retention and
treatment of complaints received by the Company regarding accounting, internal accounting controls or auditing matters, and the confidential, anonymous submissions by employees of concerns regarding
questionable accounting or accounting matters.
Because
of the role of the Board of Directors and the Audit Committee in risk oversight, the Board of Directors believes that any leadership structure that it adopts must allow it to
effectively oversee the management of the risks relating to Acceleron's operations. The Board of Directors acknowledges that there are different leadership structures that could allow it to
effectively oversee the management of the risks relating to the Company's operations and believes its current leadership structure enables it to effectively provide oversight with respect to such
risks.
BOARD COMMITTEES
The Board of Directors has a standing Audit, Compensation and Nominating and Corporate Governance Committee, each of which is comprised
solely of independent directors, and is described more fully below. Each of the Audit, Compensation and Nominating and Corporate Governance Committee operates pursuant to a written charter and each
committee reviews and assesses the adequacy of its charter and submits its charter to the Board for approval. The charters for the Audit, Compensation and Nominating and Corporate Governance
Committees are all available on our website (www.acceleronpharma.com) under "Investors" at "Corporate Governance."
9
The
following table describes which directors serve on each of the Board of Directors' committees.
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
Nominating and
Corporate
Governance
Committee
|
|
Compensation
Committee
|
|
Audit
Committee
|
|
John L. Knopf, Ph.D.
|
|
|
|
|
|
|
|
|
|
|
Jean M. George(1)
|
|
|
X
|
(2)
|
|
|
|
|
X
|
|
George Golumbeski, Ph.D.(1)
|
|
|
|
|
|
|
|
|
|
|
Edwin M. Kania, Jr.(1)
|
|
|
|
|
|
X
|
(2)
|
|
|
|
Tom Maniatis, Ph.D.
|
|
|
|
|
|
X
|
|
|
|
|
Terrance G. McGuire
|
|
|
X
|
|
|
|
|
|
X
|
|
Richard F. Pops
|
|
|
|
|
|
|
|
|
|
|
Joseph S. Zakrzewski
|
|
|
|
|
|
X
|
|
|
X
|
(3)
|
-
(1)
-
Sitting
for election in Proposal 1.
-
(2)
-
Chair
of the committee.
-
(3)
-
Interim
Chair of the Audit Committee. Upon the resignation of Dr. Evnin, Mr. Zakrzewski assumed the position of Interim Chair of the Audit
Committee, effective March 6, 2014.
Audit Committee
Our audit committee is composed of Joseph S. Zakrzewski, Jean M. George and Terrance G. McGuire, with Mr. Zakrzewski serving as
Interim Chair of the committee after the resignation of Dr. Evnin. Our board of directors has determined that Mr. Zakrzewski, Ms. George, and Mr. McGuire meet the
independence requirements of Rule 10A-3 under the Exchange Act and the
applicable listing standards of NASDAQ. Our board of directors has determined that Joseph S. Zakrzewski is an "audit committee financial expert" within the meaning of the Securities and Exchange
Commission, or SEC, regulations and applicable listing standards of NASDAQ. The audit committee's responsibilities include:
-
-
appointing, approving the compensation of, and assessing the qualifications, performance and independence of our
independent registered public accounting firm;
-
-
pre-approving audit and permissible non-audit services, and the terms of such services, to be provided by our independent
registered public accounting firm;
-
-
reviewing the audit plan with the independent registered public accounting firm and members of management responsible for
preparing our financial statements;
-
-
reviewing and discussing with management and the independent registered public accounting firm our annual and quarterly
financial statements and related disclosures as well as critical accounting policies and practices used by us;
-
-
reviewing the adequacy of our internal control over financial reporting;
-
-
establishing policies and procedures for the receipt and retention of accounting-related complaints and concerns;
-
-
recommending, based upon the audit committee's review and discussions with management and the independent registered
public accounting firm, whether our audited financial statements shall be included in our Annual Report on Form 10-K;
-
-
monitoring our compliance with legal and regulatory requirements as they relate to our financial statements and accounting
matters;
10
-
-
preparing the audit committee report required by the rules of the SEC to be included in our annual proxy statement;
-
-
viewing all related party transactions for potential conflict of interest situations and approving all such transactions;
and
-
-
reviewing and discussing with management and our independent registered public accounting firm our earnings releases and
scripts.
During
the year ended December 31, 2013, the Audit Committee met six times. The report of the Audit Committee is included in this Proxy Statement under "Report of the Audit
Committee."
Compensation Committee
Our compensation committee is composed of Edwin M. Kania, Jr., Tom Maniatis, Ph.D. and Joseph S. Zakrzewski, with Mr. Kania
serving as Chair of the committee. Our board of directors has determined that each member of the compensation committee is "independent" as defined under the applicable listing standards of NASDAQ and
meets the independence criteria set forth in Rule 10C-1. The compensation committee has the authority to delegate to subcommittees of the compensation committee any of the responsibilities of
the full committee. The compensation committee's responsibilities include:
-
-
annually reviewing and approving corporate goals and objectives relevant to the compensation of our chief executive
officer;
-
-
evaluating the performance of our chief executive officer in light of such corporate goals and objectives and determining
and approving the compensation of our chief executive officer;
-
-
reviewing and approving the compensation of our other executive officers;
-
-
appointing, compensating and overseeing the work of any compensation consultant, legal counsel or other advisor retained
by the compensation committee;
-
-
conducting the independence assessment outlined in NASDAQ rules with respect to any compensation consultant, legal counsel
or other advisor retained by the compensation committee;
-
-
annually reviewing and reassessing the adequacy of the committee charter in its compliance with the listing requirements
of NASDAQ;
-
-
reviewing and establishing our overall management compensation, philosophy and policy;
-
-
overseeing and administering our equity compensation and other compensatory plans;
-
-
reviewing and approving our equity and incentive policies and procedures for the grant of equity-based awards and
approving the grant of such equity-based awards;
-
-
reviewing and making recommendations to the board of directors with respect to director compensation; and
-
-
reviewing and discussing with management the compensation discussion and analysis to be included in our annual proxy
statement.
During
the year ended December 31, 2013, the Compensation Committee met four times.
Nominating and Corporate Governance Committee
Our nominating and corporate governance committee is composed of Jean M. George and Terrance G. McGuire, with Ms. George serving
as Chair of the committee. A vacancy exists on the
11
committee
after the resignation of Dr. Evnin. Our board of directors has determined that each member of the nominating and corporate governance committee is "independent" as defined under the
applicable listing standards of NASDAQ. The nominating and corporate governance committee's responsibilities include:
-
-
developing and recommending to the board of directors criteria for board and committee membership;
-
-
establishing procedures for identifying and evaluating board of director candidates, including nominees recommended by
stockholders;
-
-
identifying individuals qualified to become members of the board of directors;
-
-
recommending to the board of directors the persons to be nominated for election as directors and to each of the board's
committees;
-
-
developing and recommending to the board of directors a set of corporate governance principles;
-
-
articulating to each director what is expected, including reference to the corporate governance principles and directors'
duties and responsibilities;
-
-
reviewing and recommending to the board of directors practices and policies with respect to directors;
-
-
reviewing and recommending to the board of directors the functions, duties and compositions of the committees of the board
of directors;
-
-
reviewing and assessing the adequacy of the committee charter and submitting any changes to the board of directors for
approval;
-
-
consider and report to the board of directors any questions of possible conflicts of interest of board of directors
members;
-
-
provide for new director orientation and continuing education for existing directors on a periodic basis;
-
-
performing an evaluation of the performance of the committee; and
-
-
overseeing the evaluation of the board of directors and management.
During
the year ended December 31, 2013, the Nominating and Corporate Governance Committee did not meet. The Nominating and Corporate Governance Committee was created in its
present form in connection with the Company's public offering of September 19, 2013, and for the remainder of 2013 any responsibilities of the committee were satisfied by the full board of
directors.
Compensation Committee Interlocks and Insider Participation
None of the members of our compensation committee has at any time during the prior three years been one of our officers or employees.
None of our executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive
officers serving on our board of directors or compensation committee. For a description of transactions between us and members of our compensation committee and affiliates of such members, please see
"Certain Relationships and Related Party Transactions."
Code of Business Conduct and Ethics
We have adopted a code of business conduct and ethics that applies to all of our employees, officers and directors, including those
officers responsible for financial reporting. Our code of business conduct and ethics is available on our website. We intend to disclose any amendments to the code, or any waivers of its requirements,
on our website.
12
EXECUTIVE OFFICERS
Below is a list of the names, ages as of March 31, 2014 and positions, and a brief account of the business experience of the
individuals who serve as our executive officers.
|
|
|
|
|
|
Name
|
|
Age
|
|
Position
|
John L. Knopf, Ph.D.
|
|
|
61
|
|
Chief Executive Officer and President; Director (Class II)
|
Kevin F. McLaughlin
|
|
|
57
|
|
Senior Vice President, Chief Financial Officer and Treasurer
|
Matthew L. Sherman, M.D.
|
|
|
58
|
|
Senior Vice President and Chief Medical Officer
|
Steven D. Ertel
|
|
|
44
|
|
Senior Vice President and Chief Business Officer
|
Ravindra Kumar, Ph.D.
|
|
|
54
|
|
Vice President and Chief Scientific Officer
|
John D. Quisel, J.D., Ph.D.
|
|
|
42
|
|
Vice President, General Counsel and Secretary
|
EXECUTIVE OFFICER BIOGRAPHIES
Kevin F. McLaughlin
joined Acceleron in November 2010 and is our Senior Vice President,
Chief Financial Officer and Treasurer. He most recently served, from 2009 through 2010, as Senior Vice President and Chief Financial Officer of Qteros, Inc. He was a co-founder of Aptius
Education, Inc. and from 2007 through 2009 he worked as the Chief Operating Officer and a director. From 1996 through 2007, Mr. McLaughlin held several executive positions with PRAECIS
Pharmaceuticals, Inc. He joined PRAECIS as their first Chief Financial Officer where he had responsibility for private financings, partnership financings, the company's initial public offering
and subsequent stock offering. Later, Mr. McLaughlin became COO, and then President and CEO, and he served as a member of the board of directors. In this capacity he was responsible for
negotiating the sale of the company to GlaxoSmithKline. He began his career in senior financial roles at Prime Computer and Computervision Corporation. Mr. McLaughlin received a BS in business
from Northeastern University and an MBA from Babson College.
Matthew L. Sherman, M.D.
joined Acceleron in May 2006 and is our Senior Vice President and Chief Medical Officer. Previously, he served as
Senior Vice President and Chief Medical Officer at Synta Pharmaceuticals where he was responsible for clinical research, clinical operations, biostatistics, data management, regulatory affairs,
quality assurance and program management. Prior to that, Dr. Sherman worked at Genetics Institute and Wyeth Pharmaceuticals in various capacities including Therapeutic Area Director for
Oncology. While at Wyeth, Dr. Sherman provided senior oncology and hematology leadership for worldwide clinical development for both small molecule and biologic therapeutics, including the
submission and approval of Mylotarg® by the FDA. He has published numerous papers and book chapters in the field of oncology and clinical development and is named as an inventor of several
patents. Dr. Sherman is board certified in Medical Oncology and Internal Medicine and held various clinical positions at Harvard Medical School with corresponding hospital appointments at the
Dana-Farber Cancer Institute and Brigham and Women's Hospital. Dr. Sherman received an SB in chemistry from the Massachusetts Institute of Technology and an MD from Dartmouth Medical School.
Steven D. Ertel
joined Acceleron in January 2006 and is our Senior Vice President and Chief Business Officer. Mr. Ertel established
our business development function and currently leads our business development, commercial strategy and program management functions. Mr. Ertel has over 20 years of experience in the
biotechnology industry at Vivus, Inc., Genentech, Inc., Biogen Idec, Inc., and Synta. His responsibilities at these companies included program management for preclinical and
clinical stage programs, commercial strategy for clinical stage programs, market launch of a novel biologic agent, and business development. Mr. Ertel began his career in the venture capital
industry at Oxford Bioscience Partners. Mr. Ertel received a BSE in biomedical engineering from Duke University and an MBA from the Wharton School at the University of Pennsylvania.
13
Ravindra Kumar, Ph.D.
joined Acceleron in March 2004 and is currently our Vice President and Chief Scientific Officer. Dr. Kumar
established and currently leads our discovery research. Previously, Dr. Kumar worked for 12 years at Genetics Institute and Wyeth Pharmaceuticals. At Genetics Institute, Dr. Kumar
was a key member of the Small Molecule Drug Discovery group and was responsible for cell biology. Following the integration of discovery functions from GI and Wyeth Pharmaceuticals, Dr. Kumar
served as Senior Scientist in the Biological Chemistry group. Dr. Kumar is the author of several key scientific manuscripts in the area of protein glycosylation and is named as an inventor of
several patents. Dr. Kumar received his BS in chemistry from Rohilkhand University, his MS in chemistry from Meerut University, his Ph.D. from University of New Brunswick and he completed his
post-doctoral fellowship at Albert Einstein College of Medicine, in Bronx, NY.
John D. Quisel, J.D., Ph.D.
joined Acceleron in October 2006 and is our Vice President and General Counsel and Secretary. Prior to joining
us, Dr. Quisel worked at the Boston office of Ropes & Gray LLP and, prior to that, the Boston office of Foley Hoag LLP. In his work at law firms, Dr. Quisel has,
through strategic in-licensing and protection of internal research programs, assembled and licensed
product and platform focused intellectual property portfolios for numerous biotechnology ventures. Over his entire career, Dr. Quisel's experience spans many aspects of biotechnology law,
including the negotiation of intellectual property licenses and product development collaborations, patent prosecution and litigation. Dr. Quisel received an AB in biology from Harvard
University, an MS in biology from Stanford University, a Ph.D. in biology from the Massachusetts Institute of Technology and a J.D. from Harvard Law School.
14
DIRECTOR COMPENSATION
In connection with our initial public offering in 2013, our board of directors adopted a non-employee director compensation policy that
is designed to provide a total compensation package that enables us to attract and retain, on a long-term basis, high caliber non-employee directors. Under the policy, all non-employee directors will
be paid cash compensation as set forth below:
|
|
|
|
|
|
|
Annual
Retainer
|
|
Board of Directors:
|
|
|
|
|
All non-employee members
|
|
$
|
35,000
|
|
Additional retainer for Lead Independent Director
|
|
$
|
15,000
|
|
Audit Committee:
|
|
|
|
|
Chair
|
|
$
|
15,000
|
|
Non-Chair members
|
|
$
|
7,500
|
|
Compensation Committee:
|
|
|
|
|
Chair
|
|
$
|
10,000
|
|
Non-Chair members
|
|
$
|
5,000
|
|
Nominating and Corporate Governance Committee:
|
|
|
|
|
Chair
|
|
$
|
7,500
|
|
Non-Chair members
|
|
$
|
3,750
|
|
Under
our non-employee director compensation policy, each person who is initially appointed or elected to the board of directors will be eligible to receive a grant of stock options to
purchase 20,000 shares of our common stock under our 2013 Equity Incentive Plan on the date he or she first becomes
a non-employee director, which will vest quarterly in equal installments over a three-year period. In addition, each continuing non-employee director will be eligible to receive an annual option grant
to purchase 10,000 shares of our common stock, which will vest in full on the first anniversary of the grant date. The options will be granted with an exercise price equal to the fair market value of
a share of our common stock on the date of grant. In connection with the completion of our initial public offering in September 2013 and in recognition of new and increased duties of the board, in
fiscal year 2013, each board member other than Dr. Golumbeski was granted a stock option to purchase 20,000 shares of our common stock.
The
following table sets forth information concerning the compensation earned by our directors during 2013. Dr. Knopf, as an employee-director, and Dr. Golumbeski, pursuant
to policy of Celgene Corporation, each receive no additional compensation for service as a director, and, consequently, are not included in this table. The compensation received by Dr. Knopf as
an employee during 2013 is included in the "Summary Compensation Table" below.
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
Fees Paid in
Cash ($)(1)
|
|
Option Awards
($)(2)(3)
|
|
Total
($)
|
|
Anthony B. Evnin, Ph.D.
|
|
|
13,438
|
|
|
308,441
|
|
|
321,878
|
|
Jean M. George
|
|
|
12,500
|
|
|
308,441
|
|
|
320,941
|
|
Edwin M. Kania, Jr.
|
|
|
11,250
|
|
|
308,441
|
|
|
319,691
|
|
Tom Maniatis, Ph.D.
|
|
|
25,000
|
|
|
308,441
|
|
|
333,441
|
|
Terrance G. McGuire
|
|
|
9,688
|
|
|
308,441
|
|
|
318,128
|
|
Richard F. Pops
|
|
|
31,250
|
|
|
308,441
|
|
|
339,691
|
|
Joseph S. Zakrzewski
|
|
|
30,625
|
|
|
308,441
|
|
|
339,066
|
|
-
(1)
-
Amounts
represent annual cash compensation for services rendered by each member of the board of directors.
15
-
(2)
-
As
of December 31, 2013, our directors held the following aggregate number of stock options: Dr. Evnin, 20,000; Ms. George, 20,000;
Mr. Kania, 20,000; Mr. McGuire, 20,000; Dr. Maniatis, 47,500; Mr. Pops, 70,000; and Mr. Zakrzewski, 38,750. Dr. Golumbeski did not hold any stock options or
other stock awards as of December 31, 2013.
-
(3)
-
Amounts
shown reflect the grant date fair value of options awarded during fiscal 2013 determined in accordance with the Financial Accounting Standards
Board, Accounting Standards Codification Topic 718,
CompensationStock Compensation
. These amounts exclude the value of estimated
forfeitures.
The
following table sets forth as of December 31, 2013, the aggregate number of exercisable and unexercisable option awards outstanding held by our non-employee directors at that
time:
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
Name
|
|
Exercisable
|
|
Unexercisable (#)
|
|
Anthony B. Evnin, Ph.D.
|
|
|
1,667
|
|
|
18,333
|
|
Jean M. George
|
|
|
1,667
|
|
|
18,333
|
|
Edwin M. Kania, Jr.
|
|
|
1,667
|
|
|
18,333
|
|
Tom Maniatis, Ph.D.
|
|
|
26,250
|
|
|
21,250
|
|
Terrance G. McGuire
|
|
|
1,667
|
|
|
18,333
|
|
Richard F. Pops
|
|
|
76,250
|
|
|
22,500
|
|
Joseph S. Zakrzewski
|
|
|
18,855
|
|
|
19,895
|
|
EXECUTIVE COMPENSATION
Overview
The following discussion relates to the compensation of our founder, Chief Executive Officer and President, John L. Knopf, Ph.D., and
our two most highly compensated executive officers (other than our chief executive officer), Matthew L. Sherman, M.D., our Chief Medical Officer and Senior Vice President, and John D. Quisel, J.D.,
Ph.D., our General Counsel, Vice President and Secretary, who are collectively referred to in this Proxy Statement as our named executive officers. Each year, our compensation committee reviews and
determines the compensation of our executive officers, including our named executive officers. Our executive compensation program is designed to attract and retain a highly skilled team of key
executives and to align the compensation of our executives with the interests of our shareholders by rewarding the achievement of short- and long-term strategic financial goals, which we believe
serves to enhance short- and long-term value creation for our shareholders.
Elements of Executive Compensation
The compensation of our named executive officers consists of base salary, annual cash bonuses, equity awards and employee benefits that
are made available to all salaried employees. Our named executive officers are also entitled to certain compensation and benefits upon certain terminations of employment and certain change of control
transactions pursuant to employment agreements. In addition to the factors discussed below, the compensation committee also considers information from Dr. Knopf, who as our Chief Executive
Officer regularly discusses compensation issues with the Chairperson of the compensation committee and meets with the compensation committee to discuss these matters. Dr. Knopf also provides
the compensation committee and board of directors with his evaluation of the performance of the named executive officers other than himself.
Base Salaries.
Base salaries for our named executive officers are determined based on the scope of each officer's
responsibilities along with his
respective experience and contributions to the company. Base salaries for our named executive officers are determined annually by our compensation committee, subject to review by our board of
directors. When reviewing base salaries for increase, our
16
compensation
committee takes factors into account such as each officer's experience and individual performance, the company's performance as a whole, data from surveys of compensation paid by
comparable companies, and general industry conditions, but does not assign any specific weighting to any factor. For fiscal 2013, our board of directors approved a base salary of $380,662 for
Dr. Sherman and $319,300 for Dr. Quisel, representing an increase of 4.5% and 3.0%, respectively, from the base salary for each such executive in 2012. Dr. Knopf's base salary did
not increase in 2013.
Annual Cash Bonuses.
Our annual cash bonus program promotes and rewards the achievement of key strategic and business goals. For
fiscal 2013, the
target annual bonus as a percentage of base salary for each of Dr. Knopf, Dr. Sherman and Dr. Quisel remained at 50%, 30% and 30%, respectively.
At
the beginning of fiscal 2013, our compensation committee established corporate performance goals, each having a designated weighting, that included key strategic and financial goals
of the company relating to research and the company's clinical pipeline, process development and manufacturing, business development and the achievement of financial objectives. At the end of the 2013
fiscal year, our compensation committee met and evaluated the performance of the company against the specified performance goals. Based on its evaluation, our compensation committee recommended
payment of 2013 annual bonuses at the target level for all employees covered under this program and above the target level for members of our management team, including our named executive officers,
after considering the outstanding performance of the company, the achievement of the company performance goals above the target level in fiscal 2013 and the successful completion of important
financing activities in fiscal 2013, including the successful completion of our initial public offering. Our board of directors approved the recommendations of our compensation committee and each of
Drs. Knopf, Sherman and Quisel received a cash bonus for 2013 equal to $300,000, $171,315 and $143,680, respectively, representing a payment of 75%, 45% and 45%, respectively, of each executive's base
salary.
Equity Awards.
Our named executive officers participate in our Acceleron Pharma Inc. 2003 Stock Option and Restricted Stock
Plan, which we
refer to as the "2003 Plan". Our named executive officers also participate in our Acceleron Pharma Inc. 2013 Equity Incentive Plan, which we refer to as the "2013 Equity Incentive Plan". Grants
under the 2003 Plan and the 2013 Equity Incentive Plan, including those made to our named executive officers, generally consist of stock option awards subject to time-based vesting. Awards that are
subject to time-based vesting generally vest either in quarterly installments over four years or vest as to 25% of the shares subject to the option after one year and thereafter continue to vest in
quarterly installments over the following three years, generally subject to continued employment. During fiscal 2013, each of Drs. Knopf, Sherman and Quisel was awarded a stock option under the 2013
Equity Incentive Plan to purchase 110,000, 29,000 and 29,000 shares of our common stock, respectively, in each case vesting in equal quarterly installments over four years. Stock option awards serve
to align the interests of our named executive officers with our shareholders,
because no value is created unless the value of our common stock appreciates after grant. They also encourage retention through the use of time-based vesting. Pursuant to agreements with certain
members of senior management, including our named executive officers, a portion of the executive's stock option and restricted stock awards will vest automatically as of the date of a change of
control and all or a portion of the executive's stock option and restricted stock awards may vest upon certain terminations of employment.
Benefits.
We provide modest benefits to our named executive officers. These benefits and perquisites, such as participation in
our 401(k) plan and
basic health and welfare benefit coverage, are available to all of our eligible employees.
Employment Agreements and Change of Control Agreements.
Drs. Knopf, Sherman and Quisel have entered into employment agreements
with us that include
severance, change of control, and restrictive covenant provisions. We believe that change of control arrangements provide our executives with
17
security
that will likely reduce any reluctance they may have to pursue a change of control transaction that could be in the best interests of our stockholders. We also believe that reasonable
severance and change of control benefits are necessary in order to attract and retain high-quality executive officers.
Summary Compensation Table
The following table sets forth information about certain compensation awarded or paid to our named executive officers for the 2013
fiscal year.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name and Principal Position
|
|
Year
|
|
Salary
($)(1)
|
|
Option
Awards
($)(2)
|
|
Non-Equity
Incentive Plan
Compensation
($)(3)
|
|
All Other
Compensation
|
|
Total
($)
|
|
John L. Knopf, Ph.D
.
|
|
|
2013
|
|
|
400,000
|
|
|
1,696,423
|
|
|
300,000
|
|
|
237,461
|
(4)
|
|
2,633,884
|
|
Chief Executive Officer and
|
|
|
2012
|
|
|
400,000
|
|
|
1,355,300
|
|
|
200,000
|
|
|
|
|
|
1,955,300
|
|
President
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Matthew L. Sherman, M.D
.
|
|
|
2013
|
|
|
380,662
|
|
|
447,239
|
|
|
171,315
|
|
|
|
|
|
999,216
|
|
Chief Medical Officer and
|
|
|
2012
|
|
|
364,270
|
|
|
124,550
|
|
|
109,281
|
|
|
|
|
|
598,101
|
|
Senior Vice President
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
John D. Quisel, J.D., Ph.D
.
|
|
|
2013
|
|
|
319,300
|
|
|
447,239
|
|
|
143,680
|
|
|
|
|
|
910,219
|
|
General Counsel, Vice
|
|
|
2012
|
|
|
310,000
|
|
|
158,415
|
|
|
93,000
|
|
|
|
|
|
561,415
|
|
President and Secretary
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
(1)
-
Salaries
include amounts contributed by the named executive officer to our 401(k) plan.
-
(2)
-
Amounts
shown reflect the grant date fair value of options awarded during each of fiscal 2012 and 2013 determined in accordance with the Financial
Accounting Standards Board, Accounting Standards Codification Topic 718,
CompensationStock Compensation
. These amounts exclude the value of
estimated forfeitures. With respect to the performance-based option granted to Dr. Knopf in 2012, the amount included in the table assumes the highest level of performance is achieved.
-
(3)
-
Amounts
shown reflect the cash bonus amount paid to the named executive officer for each of fiscal 2012 and 2013 that was earned based on company
performance.
-
(4)
-
Represents
income imputed to Dr. Knopf in connection with the forgiveness of the entire principal amount of a promissory note entered into by him and
the Company, plus accrued interest. See "Executive Loan" below.
18
Outstanding Equity Awards at Fiscal Year-End
The following table sets forth information regarding equity awards held by our named executive officers as of December 31, 2013.
OPTION AWARDS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable
|
|
Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable
|
|
Equity Incentive
Plan Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options (#)
|
|
Option
Exercise
Price
($)(5)
|
|
Option
Expiration
Date(6)
|
|
John L. Knopf, Ph.D.
|
|
|
12,500
|
(1)
|
|
|
|
|
|
|
|
0.40
|
|
|
2/2/2015
|
|
|
|
|
12,500
|
(2)
|
|
|
|
|
|
|
|
0.40
|
|
|
3/29/2016
|
|
|
|
|
100,000
|
(2)
|
|
|
|
|
|
|
|
1.80
|
|
|
1/31/2017
|
|
|
|
|
262,500
|
(2)
|
|
|
|
|
|
|
|
5.08
|
|
|
3/27/2018
|
|
|
|
|
46,876
|
(2)
|
|
3,124
|
(2)
|
|
|
|
|
5.88
|
|
|
2/4/2020
|
|
|
|
|
65,625
|
(2)
|
|
21,875
|
(2)
|
|
|
|
|
3.88
|
|
|
12/2/2020
|
|
|
|
|
25,000
|
(2)
|
|
25,000
|
(2)
|
|
|
|
|
5.28
|
|
|
12/16/2021
|
|
|
|
|
42,969
|
(2)
|
|
94,531
|
(2)
|
|
|
|
|
5.28
|
|
|
11/13/2022
|
|
|
|
|
|
|
|
37,500
|
(3)
|
|
|
|
|
5.28
|
|
|
11/13/2022
|
|
|
|
|
|
|
|
37,500
|
(3)
|
|
|
|
|
5.28
|
|
|
11/13/2022
|
|
|
|
|
3,125
|
(4)
|
|
34,375
|
(4)
|
|
|
|
|
5.28
|
|
|
11/13/2022
|
|
|
|
|
|
|
|
110,000
|
(2)
|
|
|
|
|
24.11
|
|
|
12/5/2023
|
|
Matthew L. Sherman, M.D.
|
|
|
59,766
|
(1)
|
|
|
|
|
|
|
|
0.48
|
|
|
5/31/2016
|
|
|
|
|
32,812
|
(2)
|
|
|
|
|
|
|
|
1.80
|
|
|
1/31/2017
|
|
|
|
|
35,000
|
(2)
|
|
|
|
|
|
|
|
5.08
|
|
|
3/27/2018
|
|
|
|
|
28,125
|
(2)
|
|
9,375
|
(2)
|
|
|
|
|
3.88
|
|
|
12/2/2020
|
|
|
|
|
6,250
|
(2)
|
|
6,250
|
(2)
|
|
|
|
|
5.28
|
|
|
12/16/2021
|
|
|
|
|
6,250
|
(2)
|
|
18,750
|
(2)
|
|
|
|
|
7.12
|
|
|
12/12/2022
|
|
|
|
|
|
|
|
29,000
|
(2)
|
|
|
|
|
24.11
|
|
|
12/5/2023
|
|
John D. Quisel, J.D., Ph.D.
|
|
|
27,500
|
(1)
|
|
|
|
|
|
|
|
0.92
|
|
|
11/15/2016
|
|
|
|
|
2,500
|
(2)
|
|
|
|
|
|
|
|
1.80
|
|
|
6/12/2017
|
|
|
|
|
7,500
|
(2)
|
|
|
|
|
|
|
|
5.08
|
|
|
3/27/2018
|
|
|
|
|
12,500
|
(2)
|
|
|
|
|
|
|
|
5.88
|
|
|
12/17/2018
|
|
|
|
|
25,000
|
(2)
|
|
|
|
|
|
|
|
5.88
|
|
|
12/2/2019
|
|
|
|
|
46,875
|
(2)
|
|
15,625
|
(2)
|
|
|
|
|
3.88
|
|
|
12/2/2020
|
|
|
|
|
9,374
|
(2)
|
|
9,376
|
(2)
|
|
|
|
|
5.28
|
|
|
12/16/2021
|
|
|
|
|
9,375
|
(2)
|
|
15,625
|
(2)
|
|
|
|
|
5.28
|
|
|
6/7/2022
|
|
|
|
|
3,125
|
(2)
|
|
9,375
|
(2)
|
|
|
|
|
7.12
|
|
|
12/12/2022
|
|
|
|
|
|
|
|
29,000
|
(2)
|
|
|
|
|
24.11
|
|
|
12/5/2023
|
|
-
(1)
-
Reflects
time-based options to purchase shares of our common stock that vested as to 25% of the shares subject to the option on the first anniversary of the
vesting commencement date and thereafter vested in equal quarterly installments over the following three years, subject to the executive's continued employment.
-
(2)
-
Reflects
time-based options to purchase shares of our common stock that vest in equal quarterly installments over four years generally subject to the
executive's continued employment.
19
-
(3)
-
Reflects
time- and performance-based options granted to Dr. Knopf to purchase shares of our common stock that vest as to 1/12th of the shares
subject to the option on the date that is three months from the date on which the company achieves a specified performance condition related either to a financial goal or clinical study milestone and
that continue to vest thereafter on a quarterly basis over three years on each three-month anniversary of the initial vesting date. To the extent unvested, the option will fully vest on
September 6, 2016, generally subject to Dr. Knopf's continued employment.
-
(4)
-
Reflects
time- and performance-based options granted to Dr. Knopf to purchase shares of our common stock that vest as to 1/12th of the shares
subject to the option on the date that is three months from the date on which the company achieves a specified performance condition related to a financial goal and that continue to vest thereafter on
a quarterly basis over three years on each three-month anniversary of the initial vesting date. To the extent unvested, the option will fully vest on September 6, 2016, generally subject to
Dr. Knopf's continued employment. On December 5, 2013, our board of directors determined that the performance goal had been met on September 24, 2013. As a result,
1/12
th
of the shares subject to the stock option vested on December 24, 2013, and the remainder of the shares will vest on each of the subsequent eleven three-month
anniversaries of such date.
-
(5)
-
The
exercise price of the stock options was not less than the fair market value of a share of our common stock on the date of grant, as determined by our
board of directors based, in part, on an independent third party valuation with respect to the period prior to our initial public offering. Stock options granted in fiscal 2013 subsequent to us
becoming a public company were granted with an exercise price equal to the closing price of a share of our common stock on the date the stock option was granted.
-
(6)
-
All
stock options have a 10-year term measured from the date of grant.
Retirement Benefits
We do not maintain any qualified or non-qualified defined benefit plans or supplemental executive retirement plans that cover our named
executive officers. We offer a tax-qualified retirement plan, which we refer to as our 401(k) plan, to eligible employees, including our named executive officers. Our 401(k) plan permits eligible
employees to defer up to 100% of their annual eligible compensation, subject to certain limitations imposed by the Internal Revenue Service. Employees' elective deferrals are immediately fully vested
and non-forfeitable under this plan. We may, but are not required to, make discretionary matching contributions and other employer contributions on behalf of eligible employees under this plan. We
made matching contributions on behalf of eligible employees in fiscal year 2013, but made no such contributions on behalf of our named executive officers.
Employment Agreements
We have entered into amended and restated employment agreements with each of Drs. Knopf, Sherman and Quisel, each providing for a 2013
base salary of $400,000, $380,662
and $319,300, respectively, in each case subject to discretionary annual increases and a discretionary bonus based on performance goals in accordance with our annual cash bonus program. Each agreement
also provides for certain payments and benefits upon a qualifying termination of the executive's employment and a change of control, as described below.
Change of Control.
At the time of the consummation of a change of control, 50%, in the case of Dr. Knopf, and 25%, in the
case of Drs. Sherman
and Quisel, of any unvested stock options then held by the executive that were granted on or prior to the effective date of the executive's amended and restated employment agreement (referred to as
the amendment date) will vest.
20
Termination of Employment Without Cause or for Good Reason Following a Change of Control.
If, within one year after the
consummation of a change of
control, the executive's employment is terminated by us (or our successor) other than for cause or the executive terminates his employment for good reason (as such terms are defined in the executive's
employment agreement): (1) we will pay the executive a lump sum payment equal to the product of 1.5 times, in the case of Dr. Knopf, or one times, in the case of Drs. Sherman and Quisel,
(x) the sum of executive's then-current annual base salary plus 100% of the executive's target bonus for the year in which the termination occurs, (2) 100% of any unvested equity and
equity-based awards held by the executive at the time of such termination will fully vest, and (3) if the executive elects under COBRA or any successor law to continue participation in our
group health and/or dental plans in which the executive was participating prior to such termination, we will pay or, at our option reimburse the executive for, the full premium cost of that
participation for 18 months, in the case of Dr. Knopf, or 12 months, in the case of Drs. Sherman and Quisel, following the date the executive's employment terminates or, if
earlier, until the date the executive becomes eligible to enroll in such plans of a new employer. We will also pay the executive any base salary earned but not paid and any vacation time accrued but
not used, in each case as of the termination date.
Termination of Employment Without Cause or for Good Reason.
If the executive's employment is terminated by us other than for
cause or the executive
terminates his employment for good reason (as such terms are defined in the executive's employment agreement) under circumstances other than as described in the preceding paragraph: (1) we will
continue to pay the executive his base salary for a period of 18 months, in the case of Dr. Knopf, or 12 months, in the case of Drs. Sherman and Quisel, in accordance with our
payroll policy, (2) any unvested stock option awards the executive holds at the time of such termination of employment that are subject only to time-based vesting and that were granted on or
prior to the amendment date will vest to the extent such stock option awards would have otherwise vested over the 12 months, nine months or six months, in the case of each of Dr. Knopf,
Dr. Sherman, or Dr. Quisel, respectively, following such termination of employment, and (3) if the executive elects under COBRA or any successor law to continue participation in
our group health and/or dental plans in which the executive was participating prior to such termination, we will pay or, at our option reimburse the executive for, the full premium cost of that
participation for 18 months, in the case of Dr. Knopf, or 12 months, in the case of Drs. Sherman and Quisel. We will also pay the executive any base salary earned but not paid and
any vacation time accrued but not used, in each case as of the termination date.
Termination of Employment Due to Death or Disability.
If the executive's employment terminates due to the executive's death or
disability, all
unvested stock options then held by the executive that were granted on or prior to the amendment date will vest as of the date of termination. In the event of such a termination of employment due to
disability, to the extent we do not maintain a disability plan providing for continuation of the executive's base salary for one year following the date of such termination, during this period we will
pay the executive, at the time the executive's base salary would otherwise have been paid, an amount equal to the excess of 100% of the executive's base salary over the disability insurance benefits,
if any, actually paid to the executive. We will also pay the executive any base salary earned but not paid and any vacation time accrued but not used, in each case as of the termination date.
Severance Subject to Release of Claims and Compliance With Restrictive Covenants.
Our obligation to provide the executive with
any severance payments
or other benefits under the employment agreement is conditioned on the executive signing an effective release of claims in our favor and the executive's continued full performance of his obligations
under the Employee Confidentiality, Non-Compete and Proprietary Information Agreement relating to confidentiality, noncompetition and nonsolicitation.
21
Other Termination of Employment.
If the executive's employment is terminated for any reason other than by us without cause, by
the executive for good
reason, or due to the executive's death or disability, the executive will only be entitled to receive earned but unpaid base salary and any accrued but not used vacation as of the termination date.
280G Gross-up.
In the event that a change in ownership or control of the company under Section 280G
of the Internal Revenue Code of 1986, as amended, or the Code, and the regulations thereunder, occurs on or before the second anniversary of the amendment date, if any portion of the payments made
pursuant to the executive's employment agreement or otherwise constitutes an "excess parachute payment" within the meaning of Section 280G of the Code, we will pay the executive an additional
amount that, after the imposition of all taxes with respect to such gross-up payment equals the excise tax with respect to the excess parachute payment. If the change in ownership or control occurs
after the second anniversary of the amendment date and any portion of the payments made pursuant to the employment agreement or otherwise constitutes an excess parachute payment, the executive will be
entitled to receive an amount of such payments reduced so that no portion of the payments would constitute an excess parachute payment, or the amount otherwise payable to the executive under the
employment agreement or otherwise reduced by all applicable taxes, including the excise tax, whichever amount results in the greater amount payable to the executive.
Executive Loan
We and Dr. Knopf were parties to a Secured Promissory Note dated January 28, 2008 and amended on November 13,
2012, pursuant to which we made a loan to Dr. Knopf with a principal balance of $200,000 and an interest rate of 3.11% per annum. The outstanding balance of $237,461, including principal and
accrued and unpaid interest on the note, was forgiven immediately prior to the public filing of the registration statement in connection with our initial public offering.
Compensation Consultant
As a part of determining compensation for our named executive officers, the compensation committee has engaged Radford, an AON Hewitt
Consulting company, as an independent compensation consultant. Radford provides analysis and recommendations to the compensation committee regarding:
-
-
trends and emerging topics with respect to executive compensation;
-
-
peer group selection for executive compensation benchmarking;
-
-
compensation practices for our peer group;
-
-
compensation programs for executives and all of our associates; and
-
-
stock utilization and related metrics.
When
requested, Radford consultants attend meetings of the compensation committee, including executive sessions in which executive compensation issues are discussed. Radford reports to the
compensation committee and not to management, although Radford meets with management for purposes of gathering information for its analyses and recommendations.
In
determining to engage Radford, the compensation committee considered the independence of Radford, taking into consideration relevant factors, including the absence of other services
provided to the Company by Radford, the amount of fees the Company paid to Radford as a percentage of Radford's total revenue, the policies and procedures of Radford that are designed to prevent
conflicts of interest, any business or personal relationship of the individual compensation advisors employed by Radford with an executive officer of the Company, any business or personal relationship
the individual compensation advisors employed by Radford have with any member of the compensation committee,
22
and
any stock of the Company owned by Radford or the individual compensation advisors employed by Radford. The compensation committee has determined, based on its analysis in light of all relevant
factors, including the factors listed above, that the work of Radford and the individual compensation advisors employed by Radford as compensation consultants to the compensation committee has not
created any conflicts of interest, and that Radford is independent pursuant to the independence standards set forth in the Nasdaq listing standards promulgated pursuant to Section 10C of the
Exchange Act.
23
DIRECTOR NOMINATIONS AND COMMUNICATION WITH DIRECTORS
Director Nomination Process
The nominating and corporate governance committee recommends, and the board of directors nominates, candidates to stand for election as
directors. Stockholders may also nominate persons to be elected as directors. If a stockholder wishes to nominate a person for election as director, he or she must follow the procedures contained in
our bylaws and satisfy the requirements of Regulation 14A of the Exchange Act. To nominate a person to stand for election as a director at the annual meeting of stockholders for 2015, a
stockholder must provide our Corporate Secretary with timely notice of the nomination. To be timely, the stockholder's notice must be delivered to or mailed and received by us not earlier than the
close of business on the 120
th
day nor later than the close of business on the 90
th
day prior to the anniversary date of the prior year's annual meeting,
except that if the annual meeting is set for a date that is not within 30 days before or after such anniversary date, we must receive the notice not later than the close of business on the
tenth day following the day on which we first provide notice or public disclosure of the date of the meeting. The notice must include the following information:
As
to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made:
-
-
the name and address of the stockholder giving the notice on whose behalf the nomination or proposal is made,
-
-
the class and number of shares of stock of the Company that are, directly or indirectly, owned beneficially or of record
by the stockholder,
-
-
any option, warrant, convertible security, stock appreciation right or similar right with an exercise or conversion
privilege or a settlement payment or mechanism at a price related to any class of shares of stock of the Company or with a value derived in whole or in part from the value of any class of shares of
stock of the Company, whether or not such instrument or right shall be subject to settlement in the underlying class or series of capital stock of the Company or otherwise, each, a "Derivative
Instrument," directly or indirectly owned beneficially or of record by such stockholder and any other direct or indirect opportunity to profit or share in any profit derived from any increase or
decrease in the value of shares of stock of the Company of the stockholder,
-
-
any proxy, contract, arrangement, understanding or relationship pursuant to which such stockholder has a right to vote any
securities of the Company,
-
-
any proportionate interest in shares of the Company or Derivative Instruments held, directly or indirectly, by a general
or limited partnership in which such stockholder is a general partner or beneficially owns, directly or indirectly, an interest in a general partner,
-
-
any performance-related fees (other than an asset-based fee) that such stockholder is entitled to based on any increase or
decrease in the value of the shares of stock of the Company or Derivative Instruments,
-
-
any other information relating to such stockholder, if any, required to be disclosed in a proxy statement or other filing
required to be made in connection with solicitations of proxies for, as applicable, the proposal and/or for the election of directors in an election contest pursuant to and in accordance with
Section 14(a) of the Securities Act of 1933, or the Act, and the rules and regulations of the Securities and Exchange Commission thereunder,
-
-
a representation that the stockholder is a holder of record of the Company entitled to vote at such meeting and intends to
appear in person or by proxy at the meeting to propose such business or nomination,
24
-
-
a certification as to whether or not the stockholder has complied with all applicable federal, state and other legal
requirements in connection with the stockholder's acquisition of shares of capital stock or other securities of the Company and the stockholder's acts or omissions as a stockholder (or beneficial
owner of securities) of the Company, and
-
-
whether either the stockholder intends to deliver a proxy statement and form of proxy to holders of, in the case of a
proposal, at least the percentage of the Company's voting shares required under applicable law to carry the proposal or, in the case of a nomination or nominations, a sufficient number of holders of
the Company's voting shares reasonably believed by such stockholder to be sufficient to elect such nominee or nominees or otherwise to solicit proxies or votes from stockholders in support of such
proposal or nomination.
As
to each nominee that the stockholder proposes for election or reelection as a director:
-
-
all information relating to such nominee that would be required to be disclosed in solicitations of proxies for the
election of such nominee as a director pursuant to Regulation 14A under the Act and such nominee's written consent to serve as a director if elected,
-
-
a description of all direct and indirect compensation and other material monetary arrangements, agreements or
understandings during the past three years, and any other material relationship, if any, between or concerning such stockholder, or any of their respective affiliates or associates, on the one hand,
and the proposed nominee or any of his or her affiliates or associates, on the other hand, and
-
-
we may require any proposed nominee to furnish such other information as may be reasonably requested by us to determine
the eligibility of the proposed nominee to serve as an independent director or that could be material to a reasonable stockholder's understanding of the independence, or lack thereof, of the nominee.
Each
director will be elected by the vote of the plurality of the votes cast by the holders of the shares present in person or represented by proxy at the meeting and entitled to vote on
the election of directors.
Additional
information regarding requirements for stockholder nominations for next year's annual meeting is described in this Proxy Statement under "General
MattersStockholder Proposals and Nominations."
Contacting the Board of Directors
Stockholders wishing to communicate with our board of directors may do so by writing to the board or to the non-employee members of the
board as a group, at:
Acceleron
Pharma Inc.
128 Sidney Street
Cambridge, MA 02139
Attention: Secretary
The
communication must prominently display the legend "BOARD COMMUNICATION" in order to indicate to the Secretary that it is a communication for the board. Upon receiving such a
communication, the Secretary will promptly forward the communication to the relevant individual or group to which it is addressed. Certain items that are unrelated to the board's duties and
responsibilities may be excluded, such as spam, junk mail and mass mailings, resumes and other forms of job inquiries, surveys and business solicitations or advertisements. The Secretary will not
forward any communication determined in his or her good faith belief to be frivolous, unduly hostile, threatening, illegal or similarly unsuitable.
25
AUDIT COMMITTEE REPORT
The Audit Committee has reviewed the Acceleron audited consolidated financial statements for the year ended December 31, 2013
and has discussed these statements with management and Ernst & Young LLP, or Ernst & Young, the Company's independent registered public accounting firm. Acceleron management is
responsible for the preparation of the Company's financial statements and for maintaining an adequate system of disclosure controls and procedures and internal control over financial reporting for
that purpose. The independent registered public accounting firm audits the annual consolidated financial statements prepared by management, expresses an opinion as to whether those consolidated
financial statements present fairly the consolidated financial position, results of operations and cash flows of Acceleron Pharma Inc. in conformity with U.S. generally accepted accounting
principles and discusses any issues they believe should be raised with us. The Audit Committee is responsible for providing independent, objective oversight of the Company's accounting functions and
internal controls.
The
Audit Committee also received from, and discussed with, Ernst & Young the written disclosures and other communications that the Company's independent registered public
accounting firm is required to provide to the Audit Committee, including the matters required to be discussed by Statement on Auditing Standards No. 61, as amended (Communication with Audit
Committees), as adopted by the Public Company Accounting Oversight Board, or PCAOB, in Rule 3200T, which we refer to as SAS 61.
Ernst &
Young also provided the Audit Committee with the written disclosures and the letter required by Rule 3526 of the PCAOB. PCAOB Rule 3526 requires independent
registered public accounting firms annually to disclose in writing all relationships that in their professional opinion may reasonably be thought to bear on independence, to confirm their perceived
independence and engage in a discussion
of independence. The Audit Committee has reviewed this disclosure and has discussed with Ernst & Young their independence from Acceleron.
Based
on its discussions with management and our independent registered public accounting firm, and its review of the representations and information provided by management and our
independent registered public accounting firm, the Audit Committee recommended to the Board of Directors that the audited consolidated financial statements be included in the Acceleron Annual Report
on Form 10-K for the year ended December 31, 2013, for filing with the Securities and Exchange Commission.
Respectfully
submitted by the
Audit Committee,
Joseph
S. Zakrzewski, Interim Chair
Jean M. George
Terrance G. McGuire
26
PROPOSAL NO. 2RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM
We are asking our stockholders to ratify the Audit Committee's selection of Ernst & Young LLP, or Ernst & Young,
as our independent registered public accounting firm for the fiscal year ending December 31, 2014. Ernst & Young has served as our independent registered public accounting firm since
2006.
The
audit committee annually reviews the independent registered public accounting firm's independence, including reviewing all relationships between the independent registered public
accounting firm and us and any disclosed relationships or services that may impact the objectivity and independence of the independent registered public accounting firm, and the independent registered
public accounting firm's performance. Although ratification is not required by our bylaws or otherwise, the Board of Directors is submitting the selection of Ernst & Young to our stockholders
for ratification as a matter of good corporate practice. If the selection is not ratified, the Audit Committee will consider whether it is appropriate to select another independent registered public
accounting firm. Even if the selection is ratified, the Audit Committee in its discretion may select a different registered public accounting firm at any time during the year if the committee
determines that such a change would be in the best interests of the Company and our stockholders.
We
expect that a representative of Ernst & Young will attend the Annual Meeting and the representative will have an opportunity to make a statement if he or she so chooses. The
representative will also be available to respond to appropriate questions from stockholders.
Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Registered Public Accounting Firm
The Audit Committee pre-approves all auditing services, internal control related services and permitted non-audit services (including
the fees and terms thereof) to be performed by Ernst & Young, subject to the de minimis exception for non-audit services that are approved by the Audit Committee prior to the completion of an
audit. The Audit Committee may delegate pre-approval authority to one or more members of the Audit Committee consistent with applicable law and listing standards, provided that the decisions of such
Audit Committee member or members must be presented to the full audit committee at its next scheduled meeting.
Principal Accountant Fees and Services
We regularly review the services and fees of our independent accountants. These services and fees are also reviewed by the Audit
Committee on an annual basis. The aggregate fees billed for the fiscal years ended December 31, 2013 and 2012 for each of the following categories of services are as follows:
|
|
|
|
|
|
|
|
Fee Category
|
|
2012
|
|
2013
|
|
Audit Fees
|
|
$
|
145,000
|
|
$
|
1,144,055
|
|
Audit Related Fees
|
|
$
|
|
|
$
|
|
|
Tax Fees
|
|
$
|
31,935
|
|
$
|
45,215
|
|
All Other Fees
|
|
$
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Fees
|
|
$
|
176,935
|
|
$
|
1,189,270
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Audit Fees.
Consist of aggregate fees for professional services provided in connection with the annual audit of our consolidated
financial
statements, the review of our quarterly condensed consolidated financial statements, consultations on accounting matters directly related to the audit, and comfort letters, consents and assistance
with and review of documents filed with the SEC.
27
Audit-Related Fees.
Consist of aggregate fees for accounting consultations and other services that were reasonably related to the
performance of
audits or reviews of our consolidated financial statements and were not reported above under "Audit Fees". There were no audit-related fees for the years ended December 31, 2012 or 2013.
Tax Fees.
Consist of aggregate fees for tax compliance, tax advice and tax planning services including the review and preparation of our
federal and
state income tax returns.
All Other Fees.
Consist of aggregate fees billed for products and services provided by the independent registered public accounting
firm other than
those disclosed above. There were no other fees for the years ended December 31, 2012 or 2013.
The
Audit Committee pre-approved all services performed since the pre-approval policy was adopted.
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE
FOR
THE RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG AS THE COMPANY'S
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.
(PROPOSAL 2 ON YOUR PROXY CARD)
28
BENEFICIAL OWNERSHIP OF COMMON STOCK
The following table sets forth certain information as of March 31, 2014 (unless otherwise specified), with respect to the
beneficial ownership of our common stock by each person who is known to own beneficially more than 5% of the outstanding shares of common stock, each person currently serving as a director, each
nominee for director, each named executive officer (as set forth in the Summary Compensation Table above), and all directors and executive officers as a group.
Shares
of common stock subject to options, restricted stock units or other rights to purchase which are now exercisable or are exercisable within 60 days after March 31,
2014 are to be considered outstanding for purposes of computing the percentage ownership of the persons holding these options or other rights but are not to be considered outstanding for the purpose
of computing the percentage ownership of any other person. As of March 31, 2014, there were 31,339,135 shares of common stock outstanding. Unless otherwise indicated, the address for each
beneficial owner is c/o John Quisel, 128 Sidney Street, Cambridge, MA 02139.
|
|
|
|
|
|
|
|
Name and address of beneficial owner
|
|
Number of shares
beneficially owned
|
|
Percentage of shares
beneficially owned
|
|
5% or greater stockholders:
|
|
|
|
|
|
|
|
Polaris Venture Partners, and related funds(1)
|
|
|
3,317,136
|
|
|
10.5
|
%
|
1000 Winter Street, Suite 3350
|
|
|
|
|
|
|
|
Waltham, MA 02451
|
|
|
|
|
|
|
|
Venrock Partners, and related funds(2)
|
|
|
2,622,435
|
|
|
8.3
|
%
|
55 Cambridge Parkway, Suite 100
|
|
|
|
|
|
|
|
Cambridge, MA 02142
|
|
|
|
|
|
|
|
Advanced Technology Ventures, and related funds(3)
|
|
|
2,662,092
|
|
|
8.5
|
%
|
500 Boylston Street, Suite 1380
|
|
|
|
|
|
|
|
Boston, MA 02116
|
|
|
|
|
|
|
|
Celgene Corporation(4)
|
|
|
3,511,866
|
|
|
11.2
|
%
|
86 Morris Avenue
|
|
|
|
|
|
|
|
Summit, NJ 07901
|
|
|
|
|
|
|
|
Flagship Ventures(5)
|
|
|
2,276,479
|
|
|
7.3
|
%
|
1 Memorial Drive
|
|
|
|
|
|
|
|
Cambridge, MA 02142
|
|
|
|
|
|
|
|
OrbiMed Advisors LLC(6)
|
|
|
2,272,819
|
|
|
7.2
|
%
|
601 Lexington Avenue, 54
th
Floor
|
|
|
|
|
|
|
|
New York, NY 10022
|
|
|
|
|
|
|
|
FMR LLC
|
|
|
1,803,400
|
|
|
5.8
|
%
|
245 Summer Street
|
|
|
|
|
|
|
|
Boston, MA 02210
|
|
|
|
|
|
|
|
Directors and named executive officers:
|
|
|
|
|
|
|
|
John L. Knopf, Ph.D.(7)
|
|
|
821,407
|
|
|
2.6
|
%
|
Jean M. George(8)
|
|
|
2,665,425
|
|
|
8.5
|
%
|
George Golumbeski, Ph.D.
|
|
|
|
|
|
|
|
Edwin M. Kania, Jr.(9)
|
|
|
2,284,679
|
|
|
7.3
|
%
|
Terrance G. McGuire(10)
|
|
|
3,320,469
|
|
|
10.5
|
%
|
Tom Maniatis, Ph.D.(11)
|
|
|
294,077
|
|
|
*
|
|
Richard F. Pops(12)
|
|
|
78,958
|
|
|
*
|
|
Joseph S. Zakrzewski(13)
|
|
|
22,083
|
|
|
*
|
|
Matthew L. Sherman, M.D.(14)
|
|
|
232,126
|
|
|
*
|
|
John Quisel, J.D., Ph.D.(15)
|
|
|
152,983
|
|
|
*
|
|
All executive officers and directors as a group (13 persons)(16)
|
|
|
13,079,878
|
|
|
39.8
|
%
|
-
*
-
Represents
beneficial ownership of less than one percent of our outstanding common stock.
29
-
(1)
-
Consists
of (i) 3,077,388 shares of common stock and warrants to purchase 180,518 shares of common stock held by Polaris Venture Partners
IV, L.P. and (ii) 55,846 shares of common stock and warrants to purchase 3,384 shares of common stock held by Polaris Venture Partners Entrepreneurs' Fund IV, L.P. (together with
Polaris Venture Partners IV, L.P., the Polaris Funds). North Star Venture Management 2000, LLC directly or indirectly provides investment advisory services to various venture capital
funds, including the Polaris Funds. Each of the Polaris Funds has the sole voting and investment power with respect to the shares of the Company directly held by the applicable Polaris Fund. The
respective general partners of the Polaris Funds may be deemed to have sole voting and investment power with respect to the shares held by such funds. The respective general partners disclaim
beneficial ownership of all the shares held by the Polaris Funds except to the extent of their proportionate pecuniary interests therein. The members of North Star Venture Management 2000, LLC
(the Polaris Management Members) are also members of Polaris Venture Management Co., IV, L.L.C. (the general partner of each of the Polaris Funds). As members of the general partner and North
Star Venture Management 2000, LLC, the Polaris Management Members may be deemed to share voting and investment powers for the shares held by the Polaris Funds. The Polaris Management Members
disclaim beneficial ownership of all such shares held by the funds except to the extent of their proportionate pecuniary interests therein. Mr. Terrance G. McGuire, a director of the Company,
has an assignee interest in Polaris Venture Management Co. IV, L.L.C. To the extent that he is deemed to share voting and investment powers with respect to the shares held by the Polaris Funds,
Mr. McGuire disclaims beneficial ownership of all the shares held by the funds except to the extent of his proportionate pecuniary interest therein.
-
(2)
-
Consists
of (i) 414,360 shares of common stock and warrants to purchase 20,963 shares of common stock held by Venrock Partners, L.P. (Venrock
Partners), (ii) 2,032,352 shares of common stock and warrants to purchase 102,795 shares of common stock held by Venrock Associates IV, L.P. (Venrock IV) and (iii) 49,440
shares of common stock and warrants to purchase 2,525 shares of common stock held by Venrock Entrepreneurs Fund IV, L.P. (Venrock Entrepreneurs, and together with Venrock Partners and Venrock
IV, the Venrock Entities). The sole general partner of Venrock IV is Venrock Management IV, LLC (VM4). The sole general partner of Venrock Partners is Venrock Partners
Management, LLC (VPM). The sole general partner of Venrock Entrepreneurs is VEF Management IV, LLC (VEFM4). VM4, VPM and VEFM4 disclaim beneficial ownership over all shares held by the
Venrock Entities, except to the extent of their indirect pecuniary interests therein.
-
(3)
-
Consists
of (i) 2,018,586 shares of common stock and warrants to purchase 119,322 shares of common stock held by Advanced Technology
Ventures VII, L.P. (ATV VII), (ii) 81,002 shares of common stock and warrants to purchase 4,788 shares of common stock held by Advanced Technology Ventures VII (B), L.P.
(ATV VII-B), (iii) 38,934 shares of common stock and warrants to purchase 2,301 shares of common stock held by Advanced Technology Ventures VII (C), L.P. (ATV VII-C),
(iv) 12,025 shares of common stock and warrants to purchase 711 shares of common stock held by ATV Entrepreneurs VII, L.P. (ATV VII-E), (v) 337,565 shares of common stock
and warrants to purchase 19,916 shares of common stock held by Advanced Technology Ventures VI, L.P. (ATV VI), (vi) 21,543 shares of common stock and warrants to purchase 1,271
shares of common stock held by ATV Entrepreneurs VI, L.P. (ATV VI-E) and (vii) 4,128 shares of common stock held by ATV Alliance 2003, L.P. (ATV A 2003). ATV Associates
VII, L.L.C (ATV A VII) is the general partner of ATV VII, ATV VII-B, ATV VII-C and ATV VII-E and exercises voting and dispositive authority over the shares held by
ATV VII, ATV VII-B, ATV VII-C and ATV VII-E. Voting and dispositive decisions of ATV A VII are made collectively by Michael A. Carusi, Jean M. George (one of our directors),
Steven N. Baloff, Robert C. Hower and William C. Wiberg (collectively, the ATV A VII Managing Directors). ATV A VII and each of the ATV A VII Managing Directors disclaim beneficial ownership of
the shares held by ATV VII, ATV VII-B, ATV VII-C and ATV VII-E except to the extent of their pecuniary interest therein. ATV Associates VI, L.L.C (ATV A VI) is the general partner of ATV VI and
ATV VI-E and exercises voting and dispositive authority over the shares held by ATV VI and ATV VI-E. Voting and dispositive decisions of ATV A VI are made collectively by Michael A. Carusi,
Steven N.
30
Baloff,
Pieter J. Schiller, Robert C. Hower and William C. Wiberg (collectively, the ATV A VI Managing Directors). ATV A VI and each of the ATV A VI Managing Directors disclaim beneficial ownership of
the shares held by ATV VI and ATV VI-E except to the extent of their pecuniary interest
therein. ATV Alliance Associates, L.L.C. (ATV Alliance, LLC) is the general partner of ATV A 2003 and exercises voting and dispositive authority over the shares held by ATV A 2003.
Voting and dispositive decisions of ATV Alliance, LLC are made by Jean M. George (one of our directors). ATV Alliance, LLC and Jean M. George disclaim
beneficial ownership of the shares held by ATV A 2003 except to the extent of their pecuniary interest therein.
-
(4)
-
Includes
38,979 shares of common stock that can be acquired upon the exercise of warrants to purchase shares of our common stock.
-
(5)
-
Consists
of (i) 2,146,720 shares of common stock held by Applied Genomic Technology Capital Fund, L.P. (AGTC Fund) and (ii) 129,759
shares of common stock held by AGTC Advisors Fund, L.P. (AGTC). NewcoGen Group, Inc., or NewcoGen Inc., is the general partner of AGTC Partners, L.P., which is the
general partner of each of AGTC and AGTC Fund. NewcoGen Inc. is a wholly-owned subsidiary of Flagship Ventures Management, Inc. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the
directors of Flagship Ventures Management, Inc. and may be deemed to have beneficial ownership with respect to all shares held by AGTC and AGTC Fund. Mr. Kania, one of our directors, and
Dr. Afeyan disclaim beneficial ownership over shares held by AGTC and AGTC Fund except to the extent of their pecuniary interest therein.
-
(6)
-
Consists
of (i) 509,989 shares of common stock and warrants to purchase 33,229 shares of common stock held by OrbiMed Private Investments
II, LP (OPI II), (ii) 1,362,080 shares of common stock and warrants to purchase 88,749 shares of common stock held by OrbiMed Private Investments II (QP), LP (OPI QP),
(iii) 178,679 shares of common stock and warrants to purchase 24,151 shares of common stock held by OPI II, and (iv) 66,900 shares of common stock and warrants to purchase 9,042 shares
of common stock held by OPI QP. OrbiMed Advisors LLC, or OrbiMed, a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of OrbiMed
Capital GP II LLC, which is the general partner of OPI II and OPI QP (collectively, the OrbiMed Funds). Mr. Samuel D. Isaly is the managing member of and owner of a controlling
interest in OrbiMed. Accordingly, OrbiMed and Mr. Isaly may be deemed to have voting and investment power over the shares held by OrbiMed Funds noted above. OrbiMed and Mr. Isaly
disclaim beneficial ownership with respect to such shares, except to the extent of their pecuniary interest therein, if any.
-
(7)
-
Includes
601,407 shares of common stock that can be acquired upon the exercise of outstanding options.
-
(8)
-
Consists
of shares held by the ATV Entities. By virtue of the relationships described in footnote 3 above, Ms. George may be deemed to share
beneficial ownership in the shares held by the ATV Entities. Ms. George disclaims beneficial ownership of the shares referred to in footnote 3 above. Includes 3,333 shares of common
stock that can be acquired upon the exercise of outstanding options.
-
(9)
-
Consists
of shares held by AGTC or AGTC Fund. By virtue of the relationships described in footnote 5 above, Mr. Kania may be deemed to share
beneficial ownership in the shares held by AGTC or AGTC Fund. Mr. Kania disclaims beneficial ownership of the shares referred to in footnote 5 above. Includes 3,333 shares of common stock that
can be acquired upon the exercise of outstanding options.
-
(10)
-
Consists
of shares held by Polaris Venture Partners or related funds. By virtue of the relationships described in footnote 1 above, Mr. McGuire may
be deemed to share beneficial ownership in the shares held by Polaris Venture Partners or related funds. Mr. McGuire disclaims beneficial ownership of the shares referred to in footnote 1
above. Includes 3,333 shares of common stock that can be acquired upon the exercise of outstanding options.
-
(11)
-
Includes
28,646 shares of common stock that can be acquired upon the exercise of outstanding options.
31
-
(12)
-
Includes
50,208 shares of common stock that can be acquired upon the exercise of outstanding options.
-
(13)
-
Includes
22,083 shares of common stock that can be acquired upon the exercise of outstanding options.
-
(14)
-
Includes
174,704 shares of common stock that can be acquired upon the exercise of outstanding options.
-
(15)
-
Includes
152,983 shares of common stock that can be acquired upon the exercise of outstanding options.
-
(16)
-
Includes
1,549,720 shares of common stock that can be acquired upon the exercise of outstanding options.
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
The following is a description of transactions, since January 1, 2013, to which we have been a party, in which the amount
involved exceeded or will exceed $120,000, and in which any related person had a direct or indirect material interest.
Indemnification Agreements
We have entered into indemnification agreements with each of our directors and executive officers. These agreements will require us to
indemnify these individuals and, in certain cases, affiliates of such individuals, to the fullest extent permissible under Delaware law against liabilities that may arise by reason of their service to
us or at our direction, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified.
Registration Rights Agreement
In connection with our Series F preferred stock financing, on December 22, 2011, we entered into an amended and restated
registration rights agreement with the holders of all of our then-outstanding shares of preferred stock including certain of our named executive officers and entities with which certain of our
directors are affiliated. The agreement provides that these holders, for so long as they may hold registrable securities, as defined in the agreement, have the right to demand that we file a
registration statement with respect to the common stock issued upon conversion of our preferred stock. These holders may also request that shares of common stock held by them be included in certain
registration statements that we are otherwise filing.
Right of First Refusal and Co-Sale Agreement
In connection with our Series F preferred stock financing, on December 22, 2011, we entered into an amended and restated
right of first refusal and co-sale agreement with the holders of all of our then-outstanding shares of preferred stock including certain of our named executive officers and entities with which certain
of our directors are affiliated. Pursuant to the terms of this agreement, in the event of a proposed sale of shares of our common or preferred stock, the seller was required to first offer such shares
to the company and to the other investors, subject to certain conditions and restrictions. This agreement terminated upon the completion of our initial public offering on September 24, 2013.
Voting Agreement
In connection with our Series F preferred stock financing on December 22, 2011, we entered into an amended and restated
voting agreement with the holders of all of our then-outstanding shares of preferred stock including certain of our named executive officers and entities with which certain of our
32
directors
are affiliated, with respect to the election of directors and certain other matters. All of our current directors were elected pursuant to the terms of this agreement. This agreement
terminated upon the completion of our initial public offering on September 24, 2013.
Investor Rights Agreement
In connection with our Series F preferred stock financing, on December 22, 2011, we entered into an amended and restated
investor rights agreement with the holders of all of our then-outstanding shares of preferred stock including certain of our named executive officers and entities with which certain of our directors
are affiliated. Pursuant to the terms of this agreement, we granted our investors certain information rights as well as the right to participate pro rata in any future private financing rounds. This
agreement terminated upon the completion of our initial public offering on September 24, 2013.
Transactions with Our Executive Officers, Directors and 5% Stockholders
On March 13, 2013, we repurchased shares of our common and preferred stock, as well as warrants to purchase shares of our common
stock, from UBS Juniper Crossover Fund, LLC, an affiliate of OrbiMed Advisors, for $300,000 in aggregate.
On
January 28, 2008, we entered into a secured promissory note with our chief executive officer, which was amended on November 13, 2012, with a principal balance of
$200,000 and an interest rate of 3.11% per annum. The note was secured by a pledge of shares of the company's stock under a pledge agreement dated January 28, 2008. The terms of the note
provided that it would mature on January 28, 2014, or be forgiven upon the occurrence of certain corporate events, including the filing of a registration statement with the SEC. The outstanding
principal balance and accrued and unpaid interest on the note was forgiven on August 7, 2013. See "Executive CompensationExecutive Loan".
Related Person Transactions Policy
We have adopted a related person transaction approval policy that governs the review of related person transactions. Pursuant to this
policy, if we want to enter into a transaction with a related person or an affiliate of a related person, our General Counsel will review the proposed transaction to determine, based on applicable
NASDAQ and SEC rules, if such transaction requires pre-approval by the audit committee and/or board of directors. If pre-approval is required, such matters will be reviewed at the next regular or
special audit committee and/or board of directors meeting. We may not enter into a related person transaction unless our General Counsel has either specifically confirmed in writing that no further
reviews are necessary or that all requisite corporate reviews have been obtained.
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Exchange Act requires our executive officers and directors and persons who own more than 10% of a
registered class of our equity securities to file initial reports of ownership and reports of changes in ownership with the SEC. Such persons are required by regulation of the SEC to furnish us with
copies of all Section 16(a) forms they file. Based solely on our review of the copies of such forms or written representations from certain reporting persons received by us with respect to
fiscal year 2013, we believe that our executive officers and directors and persons who own more than 10% of a registered class of our equity securities have complied with all applicable filing
requirements.
33
GENERAL MATTERS
Code of Business Conduct and Ethics and Corporate Governance Guidelines
Acceleron has adopted a Code of Business Conduct and Ethics for its directors, officers and employees, including its Chief Executive
Officer and President and Chief Operating Officer. A copy of the Company's Code of Business Conduct and Ethics may be accessed free of charge by visiting the Company's website at
www.acceleronpharma.com
and going to the "InvestorsCorporate Governance" section or by requesting a copy in writing from John Quisel,
Secretary, at our Cambridge, Massachusetts office. Acceleron intends to post on its website any amendment to, or waiver under, a provision of the Code of Business Conduct and Ethics that applies to
certain of its executive officers within four business days following the date of such amendment or waiver.
A
copy of the Corporate Governance Guidelines may also be accessed free of charge by visiting the website at
www.acceleronpharma.com
and
going to the "InvestorsCorporate Governance" section or by requesting a copy from John Quisel, Secretary, at our Cambridge, Massachusetts office.
Availability of Certain Documents
A copy of our 2013 Annual Report on Form 10-K has been posted on the internet along with this Proxy Statement. We will mail
without charge, upon written request, a copy of our 2013 Annual Report on Form 10-K excluding exhibits. Please send a written request to our Corporate Secretary at:
Acceleron
Pharma Inc.
128 Sidney Street
Cambridge, MA 02139
Attention: Secretary
Only
one copy of this proxy statement is being delivered to multiple stockholders sharing an address, unless we have received contrary instructions from one or more of the stockholders.
We will undertake to deliver promptly, upon written or oral request, a separate copy to a stockholder at a shared address to which a single copy of the proxy statement was delivered. You may make a
written or oral request by sending a written notification to our Secretary at the address above, providing your name, your
shared address, and the address to which we should direct the additional copy of the proxy statement. Multiple stockholders sharing an address who have received one copy of the proxy statement and
would prefer us to mail each stockholder a separate copy of future mailings should contact us at our principal executive offices. Additionally, if current stockholders with a shared address received
multiple copies of the proxy statement and would prefer us to mail one copy of future mailings to stockholders at the shared address, notification of that request may also be made through our
principal executive offices.
Stockholder Proposals and Nominations
Requirements for Stockholder Proposals to be Considered for Inclusion in our Proxy Materials.
To be considered for inclusion in next
year's proxy
statement, stockholder proposals must be received by our Secretary at our principal executive offices no later than the close of business on January 9, 2015.
Requirements for Stockholder Proposals to be Brought Before an Annual Meeting.
Our bylaws provide that, for stockholder nominations to
the board of
directors or other proposals to be considered at an annual meeting, the stockholder must have given timely notice thereof in writing to the Secretary at Acceleron Pharma Inc., 128 Sidney
Street, Cambridge, MA 02139. To be timely for the 2015 annual meeting, the stockholder's notice must be delivered to or mailed and received by us not earlier than the close of business on the
120
th
day nor later than the close of business on the 90
th
day prior to the anniversary date of the prior year's annual meeting, except that if the annual
meeting is set for a date that is not within 30 days before or after such anniversary date, we must receive the notice not later
34
than
the close of business on the tenth day following the day on which we first provide notice or public disclosure of the date of the meeting. Assuming the date of our 2015 annual meeting is not so
advanced or delayed, stockholders who wish to make a proposal at the 2015 annual meeting must notify us no earlier than February 20, 2015 and no later than March 23, 2015. Such notice
must provide the information required by our bylaws with respect to each matter the stockholder proposes to bring before the 2015 annual meeting.
Other Matters
As of the date of this Proxy Statement, the board of directors does not intend to present any matters other than those described herein
at the Annual Meeting and is unaware of any matters to be presented by other parties. If other matters are properly brought before the meeting for action by the stockholders, proxies will be voted in
accordance with the recommendation of the board or, in the absence of such a recommendation, in accordance with the judgment of the proxy holder.
Directions to Annual Meeting
Directions to the 2014 Annual Meeting of Stockholders, to be held at Ropes & Gray LLP, Prudential Tower, 800 Boylston
Street, Boston, MA 02199 are set forth below:
From North of Boston:
From Route 93 take exit 26, Leverett Connector/Storrow Drive, and follow to the Copley Square exit on the left.
Take a right
onto Beacon Street and follow to Exeter Street. Take a left onto Exeter Street and follow 11 blocks. Take a right on Huntington Avenue. The Prudential Center Garage will be on the right.
From West of Boston:
Follow the Mass Pike eastbound into Boston (the Mass Pike is accessible from Route 128/I-95). Get off at exit 22,
Copley
Square/Prudential Center. Follow signs for Prudential Center. This will take you directly to the Prudential Center Garage entrance, which will be on your right.
From South of Boston:
From Route 93 take exit 18, Massachusetts Avenue. Follow sign to Massachusetts Avenue and turn right. Follow
Massachusetts
Avenue for about 2 miles to Huntington Avenue. Take a right on Huntington Avenue. Take a left on Belvidere Street. The Prudential Center garage entrance will be on your right before Sovereign Bank.
From Logan Airport:
Access Boston via the Sumner Tunnel and exit onto Route 93 North. Take exit 26, Leverett Connector/Storrow Drive,
and follow to
the Copley Square exit on the left. Take a right onto Beacon Street and follow to Exeter Street. Take a left onto Exeter Street and follow 11 blocks. Take a right on Huntington Avenue. The
Prudential Center Garage will be on the right.
Parking:
The Prudential Tower is best accessed via the South Garage, which has two entrances on Huntington Avenue, one on Dalton Street
and one on
Belvedere Street. The Red and Yellow levels are both part of the South Garage. Attendant parking is available on both levels at no additional charge.
|
|
|
|
|
By Order of the Board of Directors
|
|
|
|
|
|
John L. Knopf, Ph.D.
Chief Executive Officer, President and Director
May 9, 2014
|
35
|
THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. KEEP THIS
PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY TO VOTE, MARK
BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: Signature (Joint Owners)
Signature [PLEASE SIGN WITHIN BOX] Date Date To withhold authority to vote
for any individual nominee(s), mark For All Except and write the number(s)
of the nominee(s) on the line below. 0 0 0 0 0 0 0 0 0 0000213265_1
R1.0.0.51160 For Withhold For All All All Except The Board of Directors
recommends you vote FOR the following: 1. Election of Directors Nominees 01
Jean M. George 02 George Golumbeski, PhD 03 Edwin M. Kania, Jr. ACCELERON
PHARMA INC. 128 SIDNEY STREET CAMBRIDGE, MA 02139 VOTE BY INTERNET -
www.proxyvote.com Use the Internet to transmit your voting instructions and
for electronic delivery of information up until 11:59 P.M. Eastern Time the
day before the cut-off date or meeting date. Have your proxy card in hand
when you access the web site and follow the instructions to obtain your records
and to create an electronic voting instruction form. ELECTRONIC DELIVERY OF
FUTURE PROXY MATERIALS If you would like to reduce the costs incurred by our
company in mailing proxy materials, you can consent to receiving all future
proxy statements, proxy cards and annual reports electronically via e-mail or
the Internet. To sign up for electronic delivery, please follow the
instructions above to vote using the Internet and, when prompted, indicate
that you agree to receive or access proxy materials electronically in future
years. VOTE BY PHONE - 1-800-690-6903 Use any touch-tone telephone to
transmit your voting instructions up until 11:59 P.M. Eastern Time the day
before the cut-off date or meeting date. Have your proxy card in hand when
you call and then follow the instructions. VOTE BY MAIL Mark, sign and date
your proxy card and return it in the postage-paid envelope we have provided
or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood,
NY 11717. The Board of Directors recommends you vote FOR the following
proposal: For Against Abstain 2 To ratify the selection of Ernst & Young
LLP as the Company's independent registered public accounting firm for 2014.
NOTE: Such other business as may properly come before the meeting or any adjournment
thereof. Please sign exactly as your name(s) appear(s) hereon. When signing
as attorney, executor, administrator, or other fiduciary, please give full
title as such. Joint owners should each sign personally. All holders must
sign. If a corporation or partnership, please sign in full corporate or
partnership name, by authorized officer. For address change/comments, mark
here. (see reverse for instructions) Yes No Please indicate if you plan to
attend this meeting
|
|
0000213265_2 R1.0.0.51160 Important Notice Regarding the
Availability of Proxy Materials for the Annual Meeting: The Form 10-K, Notice
& Proxy Statement is/are available at www.proxyvote.com . ACCELERON
PHARMA INC. Annual Meeting of Stockholders Friday, June 20, 2014 11:00 a.m.
Eastern Time This proxy is solicited by the Board of Directors John Quisel
and Kevin McLaughlin, or either of them, each with the power of substitution,
are hereby authorized to represent and vote the shares of the undersigned,
with all the powers which the undersigned would possess if personally
present, at the Annual Meeting of Stockholders of Acceleron Pharma Inc. to be
held on Friday, June 20, 2014 at 11 a.m. Eastern Time or at any postponement
or adjournment thereof. Shares represented by this proxy will be voted by the
stockholder in accordance with the specifications indicated on this proxy. If
no such distinctions are indicated, the Proxies will have the authority to
vote FOR all nominees and FOR Proposal 2 Ratify the Selection of Independent
Registered Public Accounting Firm. In their discretion, the Proxies are
authorized to vote upon such other business as may properly come before the
meeting. (If you noted any Address Changes and/or Comments above, please mark
corresponding box on the reverse side.) Address change/comments: Continued
and to be signed on reverse side
|
QuickLinks
GENERAL INFORMATION
PROPOSAL NO. 1ELECTION OF DIRECTORS
DIRECTORS AND CORPORATE GOVERNANCE
EXECUTIVE OFFICERS
DIRECTOR COMPENSATION
EXECUTIVE COMPENSATION
OPTION AWARDS
DIRECTOR NOMINATIONS AND COMMUNICATION WITH DIRECTORS
AUDIT COMMITTEE REPORT
PROPOSAL NO. 2RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
BENEFICIAL OWNERSHIP OF COMMON STOCK
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
GENERAL MATTERS
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024